PF-[ADDRESS_507892] OF REPEATED SUBCUTANEOUS ADMINISTRATION OF
PF-06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER 
AND ANOREXIA, FOLLOWED BY [INVESTIGATOR_204681] 18-WEEK OPEN-LABEL TREATMENT
PERIOD
Study Intervention Number: PF-06946860
Study Intervention Name: [CONTACT_82111] (N/A)
US IND Number:
EudraCT Number: Not Applicable (N/A)
Protocol Number: C3651010
Phase: 1b
Short Title: Study to Assess the Effect of PF-06946860 on Appetite Following 
Subcutaneous Administration to Patients With Anorexia and Advanced Cancer
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or 
use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.
CCICCI
PF-[ADDRESS_507893] entry  criteria and associated 
concomitant therap y requirements.  
Section 5.1: Inclusion criterion # 2: 
clarification of description of cancer 
diagnosis .
Section 5.1: I nclusion criterion # 3: 
clarification of treatment options.
Section 5.2: Exclusion criterion # 1: removed
for simplif ication.
Section 5.2: Exclusion criterion # 9 (# 8 in 
Protocol A mendment 2):clarification of HIV
diagnosis.
Section 5.2: Ex
clusion criterion # 13 (#12 in 
Protocol A mendment 2) and Section 6.5: 
clarification of description of t reatments for 
anorexia, weight loss or cachexia and minor 
update to sentence structure describing 
‘stable” .
Section 5.2: Exclusion criterion # 15(# 14 in 
Protocol 
Amendment 2) and Section 6.5: 
updates 
on the use of glucocorticoid therap y 
based on the current standard of care 
regimens common in the patient population
and timing given the primary  endpoint and 
minor update to sentence structure de scribing 
‘stable” .
Section 5.2: Exclusion criterion # 1 6(#15in 
Protocol Amendment 2) and Section 6.5: and 
minor update to sentence structure describing 
‘stable” .

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 3Section 5.2: Exclusion criterion # 20(# 19 in 
Protocol Amendment 2) minor clarification to 
add “x” to “ Inclusion of participants with 
alkaline phosphatase >[ADDRESS_507894] may  be 
acceptable if they  are deemed medicall y 
stable and fit for the study b y both 
investigator and sponsor medically  qualified 
personnel.
”  
Additional updates and clarifications wer e made 
to the following sections: 
Schedule of activities: footnote “i” was added 
to the Qualitative Phone Interview 
(participant) at the Week 4 and Earl y
Term/Discontinuation visits for flexibility . 
Sections 2.2.2
.2and [IP_ADDRESS]: updated per the 
finalized supplemental CSRs for C3651001 
and C3651002.
Section 6.1.1: update d to include details of 
investigational product dosing details and 
administration timing.
Section 9.5: added clarify ing text to the 
interim analy sis.
Appendix 13: Abbreviations.
Amendment 1 2 2June 2021 The overall rationale for this amendment is to 
provide modifications and clarifications to the 
following exclusion criteria :
Section 5.2: Exclusion criterion # 7 : 
clarification of description and timing ascites 
symptoms .
Section 5.2: 
Exclusion criterion # 15 and 
Section 6.5 :updates 
based on the current 
standard of care regimens common in the 
patient population.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 4Section 5.2: Exclusion criterion # 17: Updated 
to clarify  that receipt of at least one dose of 
PF-
06946860 is exclusionary .
Section 5.2: 
Exclusion criterion #20 : updated 
to reflect variability  of typi[INVESTIGATOR_402874].
Additional updates based on the final 6- month 
NHP study report and minor edits for consistency  
and to improve readability as follows:
SOA: footnote k: PD in footnote changed to 
GDF -15Section [IP_ADDRESS]: NOAEL C max, Cav
and AUC 168Hvalues updated to reflect final 
6-month NHP study  report.  Corresponding 
changes made to safet y margins in Table 1
and overdose text in Section 8.4
.
Section [IP_ADDRESS]: minor update in the text 
describing the total PF
-06946860 PK.
Section 2. 2.2.3: baseline GDF -15 
concentration updated from median to 
geometric mean to be consistent with 
reporting standards for the data th at will be 
included in the supplemental Clinical Study 
Reports for completed Phase 1 studies.
Section 4.3: description of dose rationale 
simplified by  [CONTACT_402881] .
Section 6.1.1: guidance provided on timing of 
IP dosing relative to standard of care 
treatment, if applicable. 
Section 8.5: administrative clarification: 
On dosing day s, pre -dose PK sample will 
be collected prior to IP administration . 
Section 8.6.1: administrative clarification s: 

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 5The actual date and time (24 hour clock 
time) of each sample will be recorded.
On dosing day s, pre -dose GDF -15 sample
will be collected prior to IP 
administration
.
Section 10.4.4 Highl y Effective Methods That 
are User Dependent
Removal of “injectable” under Combined 
(estrogen and progestogen containing)
hormonal contraception associated with 
inhibition of ovulation required template 
update.
The following i tems noted in the Protocol 
Administrative Change Letter dated [ADDRESS_507895] also been incorporated .
Modification toExclusion criterion # 1 , 
Sched ule of Activities Footnote ‘j’, 
Section [IP_ADDRESS] Qualitative Phone Interviews, 
Section 8.6.1 GDF -15, Section 10.13. 
Appendix 13: Abbreviations.
Original 
protocol18 December 2020 N/A
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and IRBs/ECs and any  protocol administrative 
clarification letter.

PF-[ADDRESS_507896] OF TABLES................................................................................................................. ..11
1. PROTOCOL  SUMMARY...................................................................................................12
1.1. Synopsis .................................................................................................................. 12
1.2. Schema .................................................................................................................... 18
1.3. Schedule of Activities .............................................................................................19
2. INTRODUCTION ...............................................................................................................2 2
2.1. Study R ationale .......................................................................................................22
2.2. Background .............................................................................................................23
2.2.1. Nonclinical Overview.................................................................................23
[IP_ADDRESS]. Nonclinical Pharmacology ........................................................[IP_ADDRESS]. Nonclinical Pharmacokinetics and Metabolism........................[IP_ADDRESS]. Nonclinical Safety .....................................................................23
2.2.2. Clinical Overview.......................................................................................24
2.3. Benefit/Risk Assessment.........................................................................................26
2.3.1. Risk Assessment .........................................................................................272.3.2. Benefit Assessment.....................................................................................282.3.3. Overall Benefit/Risk Conclusion................................................................28
3. OBJECTIVES, ESTIMANDS AND ENDPOINTS ............................................................284. STUDY DESIGN................................................................................................................ .31
4.1. Overall Design.........................................................................................................314.2. Scientific Rationale for Study Design.....................................................................32
4.2.1. Population...................................................................................................324.2.2. Duration of Dosing .....................................................................................334.2.3. Endpoints and Procedures...........................................................................33
[IP_ADDRESS]. Participant Input into Design.....................................................34
CCICCI
PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 74.4. End of Study  Definition ..........................................................................................36
5. STUDY POPUL ATION
......................................................................................................36
5.1. I nclusion Criteria .....................................................................................................36
5.2. Exclu sion Criteria ....................................................................................................38
5.3. L ifesty le Considerations ..........................................................................................41
5.3.1. Contraception ..............................................................................................41
5.4. Screen Failures ........................................................................................................41
5.5. Criteri a for Temporarily  Delay ing Enrollment/Randomization/Study  
Intervention Administration ......................................................................................42
6. STUDY INTERVENTIO N
..................................................................................................42
6.1. Study  Intervention(s) Administered ........................................................................42
6.1.1. Administration ............................................................................................43
6.2. Prepara tion/Handling/Storage/Accountability ........................................................43
6.2.1. Preparation and Dispensing ........................................................................44
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................44
6.3.1. Allocation to Study Intervention ................................................................44
6.3.2. Breaking the Blind ......................................................................................45
6.4. Study  Intervention Compliance ...............................................................................45
6.5. Concomitant Therapy ..............................................................................................45
6.5.1. Rescue Medicine .........................................................................................47
6.6. Dose Modification ...................................................................................................47
6.7. I ntervention After the End of the Study ..................................................................47
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................47
7.1. Discontinuation of Study  Intervention ....................................................................47
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_507897] to Follow -up ....................................................................................................49
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................49
8.1. Efficacy  Assessments ..............................................................................................50
8.1.1. P atient Reported Outcomes ........................................................................50

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Cancer -Related Cachexia Sy mptom Assessment –
Appetite .............................................................................................50
[IP_ADDRESS]. Cancer -Related Cachexia Sy mptom Assessment 
–Fatigue ......51
[IP_ADDRESS]. PROMI S Pain 1a .......................................................................51
[IP_ADDRESS]. Patient Global Impression of Change (PGI -C).........................51
[IP_ADDRESS]. Qualitative Phone Interviews ....................................................51
8.2. Safet y Assessments .................................................................................................51
8.2.1. Phy sical Examinations ................................................................................52
8.2.2. Clinical Safety  Laboratory  Assessments ....................................................52
8.2.3. Pregnancy  Testing ......................................................................................52
8.3. Adverse Events and Serious Adverse Events
..........................................................53
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......53
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................54
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
...................54
8.3.2. Method of Detecting AEs and SAEs ..........................................................54
8.3.3. Follow -up of AEs and SAEs .......................................................................54
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................55
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ................................ ................................ ................................ .......... 55
[IP_ADDRESS]. Exposure During Pregnancy ......................................................55
[IP_ADDRESS]. Exposure During Breastfeeding ................................................57
[IP_ADDRESS]. Occupational Exposure .............................................................57
8.3.6. Cardiovascular and Death Events ...............................................................57
8.3.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................[ADDRESS_507898] .............................................................58
[IP_ADDRESS]. Lack of Efficacy ........................................................................58
8.3.9. Medical Device Deficiencies ......................................................................58
8.3.10. Medication Errors .....................................................................................58
8.4. Treatment of Overdose
............................................................................................59
8.5. Pharmacokinetics ....................................................................................................60
8.6. Pharmacod ynamics ..................................................................................................60

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 98.6.1. GDF -15 .......................................................................................................60
8.6.2. Bod y Weight ...............................................................................................61
8.7.Genetics ...................................................................................................................62
8.7.1. Specified Genetics ......................................................................................62
8.7.2. Banked Biospecimens for Genetics ............................................................62
8.8. Biomarkers ..............................................................................................................62
8.8.1. Specified Gene Expression (RNA) Research .............................................62
8.8.2. Specified Protein Research .........................................................................62
8.8.3. Specified Metabolomic Research ...............................................................62
8.9. I mmunogenicit y Assessments .................................................................................62
8.10. Health Economics .................................................................................................63
9. STATI STICAL CONSI DERATIONS
................................................................................63
9.1.Estimands and Statistical Hy potheses .....................................................................63
9.1.1. Estimands ....................................................................................................63
9.2. Sample Size Determination .....................................................................................65
9.3. Analy sis Sets ...........................................................................................................66
9.4. Statistical Analy ses.................................................................................................67
9.4.1. G eneral Considerations ...............................................................................67
[IP_ADDRESS]. Analy ses for Continuous Endpoints ..........................................67
9.4.2. Primary  Endpoint(s) ....................................................................................67
9.4.3. Secondary  Endpoint(s) ................................................................................68
9.4.4. Tertiary /Exploratory  Endpoint(s) ...............................................................68
9.4.5. Other Anal yses............................................................................................68
9.5.Interim Anal yses.....................................................................................................69
9.6. Data Monitoring Committee or Other Independent Oversight Committee ............. 69
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ..........................................................................................................70
10.1. Appendix 1: Regulatory , Ethical, and Stud y Oversight Considerations ...............70
10.1.1. Regulatory and Ethical Considerations ....................................................70
[IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................70
10.1.2. Financial Disclosure .................................................................................71

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 1010.1.3. I nformed Consent Process ........................................................................71
10.1.4. Data Protection .........................................................................................72
10.1.5. Dissemination of Clinical Study  Data ......................................................72
10.1.6. Data Qualit y Assurance ............................................................................74
10.1.7. Source Documents ....................................................................................75
10.1.8. Study  and Site Start and Closure ..............................................................75
10.1.9. Publication Policy
.....................................................................................76
10.1.10. Sponsor’s Qualified Medical Personnel .................................................77
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................78
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recordi ng, 
Evaluating, Follow -up, and Reporting ......................................................................79
10.3.1. Definition of AE .......................................................................................79
10.3.2. Definition of SAE
.....................................................................................80
10.3.3. Recording/Reporting and Follow- up of AEs and/or SAEs .......................82
10.3.4. Reporting of SAEs
....................................................................................85
10.4. Appendix 4: Contraceptive Guidance ...................................................................86
10.4.1. Male Participant Reproductive Inclusion Criteria
....................................86
10.4.2. Female Participant Reproductive Inclusion Criteria .................................86
10.4.3. Woman of Childbearing Potential ............................................................87
10.4.4. Contraception Methods .............................................................................88
10.5. Appendix 5: Genetics
............................................................................................89
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -up Assessments ........90
10.7. Appendix 7: Cancer
-Related Cachexia Sy mptom Assessment – Appetite ...........92
10.8. Appendix 8: Cancer -Related Cachexia Sy mptom Assessment – Fatigue .............93
10.9. Appendix 9: PROMI S Pain 1a ..............................................................................94
10.10. Appendix 10: Patient Global I
mpression of Change ................................ ........... [ADDRESS_507899] ...............................................................................96
10.11.1. Telehealth Visits .....................................................................................96
10.11.2. Nutritional Advice Consult
.....................................................................96
10.11.3. Home Health Visits ................................ ................................ ................. 96
10.12. Appendix 12 Alternative Measures During Public Emergencies ........................97
10.12.1. Eligibility ................................................................................................97

PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 1110.12.2. Adverse Events and Serious Adverse Events .........................................97
10.13. Appendix 13: Abbreviations ...............................................................................[ADDRESS_507900] OF TABLES
 
 
Table 2. Protocol-Required Safety Laboratory Assessments .................................78CCI
PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 121.PROTOCOL SUMMARY 
1.1.Synopsis 
Short Title: Study  to Assess the Effect of PF -06946860 on Appetite Following 
Subcutaneous Administration to Patients with Anorexia and Advanced Cancer .
Background and Rationale
Cachexia, or anorexia -cachexia sy ndrome, is a metabolic disorder and comorbidity  that 
occurs with several chronic diseases including cancer, heart failure, chronic obstructive 
pulmonary  disease (COPD), and chronic kidney  disease (CKD).  Cachexia is multifactorial, 
and is characterized b y loss of appetite, weight, and skeletal muscle, leading to fatigue, 
functional impairment, increased treatment -related toxicity , poor qualit y of life, and reduced 
survival.  Anorexia is a key  component of the cache ctic phenot ype.1Ameta -analysis of 
30randomi zed controlled trials from the European Organisation for Research and Treatment 
of Cancer (EORTC) showed that loss of appetite correlates with poor survival in ca ncer 
patients with advanced disease .2
The cy tokine growth differentiation factor 15 (GDF -15), also known as Macrophage 
Inhibitory  Cytokine 1 (MIC -1), is a member of the transforming growth factor beta (TGF ) 
superfamil y.  In healthy individuals the major source of circulating GDF -15 is believed to be 
the liver, although it is also expressed by  [CONTACT_10521] s, lung and adipose tissue ;3and during 
pregnancy  it is highly  expressed by  [CONTACT_402882] .4GDF -15 is also secreted b y tumor 
cells, macrophages and damaged cells.5-8Inseveral chronic conditions such as cancer, heart 
failure, COPD, and CKD, circulating GDF-15 concentrations are markedl y elevated 
compared to healthy  levels .9-12
Elevated GDF -15 is associated with weight loss and anorexia -cachexia in patients with 
cancer .13-16It is hy pothesized that anorexia -cachexia in patients with cancer is largel y 
mediated via GDF -15 and that suppression of GDF -15 in these patients may  lead to 
improvement in serious aspects of their disease such as anorexia leading to unintended 
weight loss, fatigue and impai red mobility .  PF-06946860 is a recombinant humanized 
monoclonal antibody  (immunoglobulin gamma -
1 with kappa light chains [IgG1κ]) directed 
against GDF -15.  This anti -GDF -15 humanized monoclonal antibody  (mAb) binds to the 
GDF -[ADDRESS_507901] of repeated subcutaneous 
administration of PF -06946860 on appetite in participants with advanced cancer, anorexia 
and elevated circulating GDF -15 levels. The study  will also assess secondary  and 
exploratory  endpoints including fatigue, safet y and body weight. 

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 13Objectives, Estimands and Endpoints
Part A
Objectives Endpoints Estimands
Primary
 To evaluate the early effect of 
PF-06946860 compared to 
placebo on appetite in 
participants with anorexia and 
advanced cancer. Change from baseline for patient 
reported 7 -day recall 
Cancer -Related Cachexia 
Symptom Assessment –Appetite 
score, at Week 4. Estimand 1 (similar to 
“hypothetical”) is intended to 
provide a population level 
estimate of the treatment effect on 
the change from baseline Appetite 
score for PF -06946860 compared 
to placebo in all evaluable 
participants under the scenario of 
no discontinuation of study 
intervention and without the 
potential confounding effects of 
prohibited medications, regardless 
of the participants’ complia nce 
with dosing ( ie,using the 
Censored analysis set).
Secondary
 To evaluate the effect of 
PF-06946860 compared to 
placebo on appetite in 
participants with anorexia and 
advanced cancer. Change from baseline for patient 
reported 7 -day recall 
Cancer -Related Cachexia 
Symptom Assessment –Appetite 
score, at Weeks 1, 2, 3, 5 and 6. Estimand 1, as above.
 To evaluate the effect of 
PF-06946860 compared to 
placebo on fatigue in 
participants with anorexia and 
advanced cancer. Change from baseline for patient
reported 7 -day recall 
Cancer -Related Cachexia 
Symptom Assessment -Fatigue 
score, at Weeks 1, 2, 3, 4, 5 and 6. Estimand 2(similar to 
“hypothetical”) is intended to 
provide a population level estimate 
of the treatment effect on the 
change from baseline F atigue score 
for PF -06946860 compared to 
placebo in all evaluable participants 
under the scenario of no 
discontinuation of study 
intervention and without the 
potential confounding effects of 
prohibited medications, regardless 
of the participants’ complianc e 
with dosing ( ie,using the Censored 
analysis set).
 To characterize the safety and 
tolerability of repeated 
subcutaneous administrations of 
PF-06946860 compared to 
placebo in participants with 
anorexia and advanced cancer. Incidence of adverse events and
laboratory abnormalities, in Part 
A of the study.There are no defined estimands for 
these endpoints and they will be 
analyzed using [COMPANY_007] data 
standards, as applicable.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 14Objectives Endpoints Estimands
Tertiary/Exploratory: 
 To evaluate the effect of 
PF-06946860 compared to 
placebo on body w eight in 
participants with anorexia and 
advanced cancer. Change from baseline in body 
weight, at Weeks 3, 4 and 6 .N/A
 To explore the relationship 
between pain and appetite and 
fatigue in participants with 
anorexia and advanced cancer . Change from baseline score for 
patient reported 7 -day recall 
PROMIS -Pain 1a, Cancer -Related 
Cachexia Symptom Assessment-
Fatigue score and Cancer-Related 
Cachexia Symptom 
Assessmen t-Appetite score at 
Weeks 1, 2, 3, 4, 5 and 6.N/A
 To assess patient global 
impression of change of 
appetite and fatigue in 
participants with anorexia and 
advanced cancer . PGI-C (appetite), at Weeks 4 
and6.
 PGI-C (fatigue), at Weeks 4 
and-6.N/A
 To cha racterize the unbound and 
total PKof PF -06946860 
administered in participants with 
anorexia and advanced cancer . Serum unbound and total 
concentrations of PF -06946860,
on Day 1 and Weeks 3, 4 and 6.N/A
 To characterize the effect of 
PF-06946860 administration on 
circulating GDF -15
concentrations in participants 
with anorexia and advanced 
cancer. Serum concentrations of total 
GDF -15; and if feasible, unbound 
GDF -15,on Day 1 and W eeks 3, 
4 and 6.N/A
 To assess the immunogenicity
of PF -06946860 administered in 
participants with anorexia and 
advanced cancer. Incidence of ADA and, if 
applicable, NAb, in Part A of the 
study .N/A

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 15Part B 
In addition, the following objectives will be evaluated using data from Part B, as data permit:
Objectives Endpoints Estimands
Tertiary/Exploratory:
 To assess appetite in participants with 
anorexia and advanced cancer, during 
the open -label treatment period. Change from baseline for patient 
reported 7 -day recall Cancer -Related 
Cachexia Symptom 
Assessment -Appetite score, weekly 
from Week 7 to 24. N/A
 To assess fatigue in participants with 
anorexia and advanced cancer, during 
the open -label treatment period. Change from baseline for patient 
reported 7 -day recall Cancer -Related 
Cachexia Symptom A ssessment -Fatigue 
score, weekly from Week 7 to 24.N/A
 To characterize the safety and 
tolerability of repeated subcutaneous 
administrations of PF -06946860 in 
participants with anorexia and advanced 
cancer, during the open -label treatment 
period. Incidence of adverse events and 
laboratory abnormalities, in Part B of 
the study .There are no defined 
estimands for these 
endpoints and they 
will be analyzed using 
[COMPANY_007] data standards, 
as applicable.
 To assess body weight in participants 
with anorexia and advanced cancer, 
during the open -label treatment period. Change from baseline in body weight, 
at Weeks 12, 15, 18, 21 and 24.N/A
 To explore the relationship between
pain and appetite/fatigue in participants 
with anorexia and advanced cancer, 
during the open -label treatment period. Change from baseline score for patient 
reported 7 -day recall PROMIS- Pain 1a,
Cancer -Related Cachexia Symptom 
Assessment -Fatigue score and Cancer-
Related Cachexia Symptom 
Assessment –Appetite score, weekly 
from Week 7 to 24.N/A
 To assess patient global impression of 
change of appetite and fatigue in 
participants with anorexia and advanced 
cancer, during the open -label treatment 
period. PGI-C (appetite), at Week 24.
 PGI-C (fatigue), at Week 24.N/A
 To characterize the unbound and total 
PKof PF -06946860 administered in 
participants with anorexia and advanced 
cancer, during the open -label treatment 
period. Serum unbound and total concentr ations 
of PF -06946860, at Weeks 12, 18 
and24.N/A
 To characterize the effect of 
PF-06946860 administration on 
circulating GDF -15concentrations in 
participants with anorexia and advanced 
cancer, during the open -label treatment 
period. Serum concentration s of total GDF -15; 
and if feasible, unbound GDF-15, at 
Weeks 12, 18 and 24.N/A

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 16Objectives Endpoints Estimands
 To assess the immunogenicity of 
PF-06946860 administered in 
participants with anorexia and advanced 
cancer, during the open -label treatment 
period. Incidence of ADA and, if applicable, 
NAb, in Part B of the study.N/A
Overall Design
This is a Phase 1b study  in patients with advanced cancer, anorexia and elevated circulating 
GDF -15 levels. The study  will be conducted in 2 parts. The initial 6 -week treatment period 
will be a randomized, double -blind, placebo -controlled, parallel group study . Participants 
who meet the entry  criteria will be randomized to study  drug (PF -06946860 or placebo).  The 
6-week double -blind dosing period will consist of a total of [ADDRESS_507902] ered 
3weeks apart (Q3W).  The 6 -week double -blind treatment period will be followed by  
[CONTACT_402883] -label treatment (OLT) with PF -[ADDRESS_507903] 2 clinic visits (Screening and Randomization) with 
the investigator. The Screening visit will occur no more than 28 day s and no less than 
5days, prior to Randomization. The 5 -day minimum duration between Screening and 
Randomization visits will ensure t hat all necessary  data (including GDF -15 level) are 
available to inform the investigator’s assessment of eligibility . 
All study  visits following Randomization may  be conducted by  a visiting Health Care 
Professional (HCP) at the patient’s home. During sel ected home -HCP visits, the investigator 
will conduct Telehealth consults with the participant in order to assess patient safet y. Should 
the participant elect, at Randomization, to have all subsequent Part A study  visits carried out 
at the investigator sit e rather than at home, this preference may  be accommodated. 
During the W eek [ADDRESS_507904] with all participants (whether participating in the 6- week double -blind 
only, or the OLT period) will be scheduled to occur at least [ADDRESS_507905] may  be done via a phone 
call, telehealth , at home or in the clinic, per investigator judgement. For study  part B, a 
home -HCP +TeleHealth (or in -Clinic) visit will be conducted. Additional follow -up may  be 
conducted for safety  evaluation, at the discretion of the investigator.

PF-[ADDRESS_507906] such that 
approximately 30 evaluable participants complete the 6-week double-blind portion of the study. 
The study will be randomized in approximately a 2:1 ratio (27 active: 13 placebo).Intervention Groups and Duration
Intervention Name [INVESTIGATOR_16335]-06946860 Placebo
ARM Name [INVESTIGATOR_16335]-06946860 Double-Blind Treatment 
followed by [CONTACT_301985]-Label TreatmentPlacebo Double-Blind Treatment followed by 
[CONTACT_301985]-Label Treatment
Type Biologic Placebo
Dose Formulation Solution for injection Solution for injection
Unit Dose Strength(s)  Placebo
Dosage Level(s) Placebo Q3Weeks
Route of Administration Subcutaneous Subcutaneous 
Investigational Medicinal 
Product (IMP) and 
Noninvestigational 
Medicinal Product (NIMP)IMP IMP
Sourcing Provided centrally by [CONTACT_402884] 
6-mL glass vial with a 1 mL withdraw volume.  Each vial will be labeled as 
required per country requirement.Study intervention will be provided in 6-mL 
glass vial with a 1 mL withdraw volume.  Each vial will be labeled as required per 
country requirement.
Current/Former Name(s) 
or Alias(es)Not applicable Not applicable
Data Monitoring Committee or Other Independent Oversight Committee: No
Statistical MethodsRefer to Section 9 .CCICCI
PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 181.2. Schema
CCICCI
PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 191.3. Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evalua tions or 
assessments required to protect the well-being of the participant.
PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 20Screening Part A: Double-Blind Part B: Open-Label Part A: 
Follow-upbPart B: 
Follow-
upcEarly Term/
Discontinuation
Visit Identifier
Abbreviations, see Appendix 13v1 v2 v3 v4 v5 v6 v7 v8 v9 v10 v11 v12 v13
Study Week (relative to Day 1) Rand wk3 wk4a,bwk6 wk9 wk12 wk15 wk18 wk21 wk24
Study Day (relative to Day 1 dosing) -28 to -5 Day 1 22 29 43 64 85 106 127 148 169 50 197
Visit Window (days) ±1 ±1 ±1 ±3 ±3 ±3 ±3 ±3 ±3 +7 +7
Clinic Visit  X X
Telehealth VisitdX X XX X X X X X
At-Home/Residential Care Facility Home-HCP 
VisitdX X XXX X X XX X X X
Informed Consent and Registration X
Informed consent (caregiver)eX
Review of Eligibility Criteria X X
Randomization X
Administration of blinded PF-06946860/placebo X X
Administration of open-label PF-[ADDRESS_507907] Prior or Concomitant treatments X X→→→→→→ →→→ XX X
Monitor Serious/nonserious AEs X X→→→→→→ →→→ XX X
Review contraception use X X X XXX X X XX X X X
Physical Examination (Height at Screening only)fX XX X
PRO (weekly) 7-day recall: appetite, fatigue, paingX Xh→→→→i→i→i→i→i→i XiXiX
PRO PGI-C: appetite and fatigue X XXiX
Qualitative Phone Interview (participant)jXiXiXi
Qualitative Phone Interview (care giver)e,jX X
Weight + Body Composition via BIA (BIA not at 
Screen)X XhXiXiXiXiXiXiXiXiXiXiXiX
Blood and Urine samples: Clinical Lab Tests, 
Table 2X X X XXX X X XX X X X
Pregnancy Test for female participants of 
childbearing potential (Blood and/or Urine)X X XX X X
Blood sample for GDF-15kX X X X XXiXiXiXiXiX
Blood sample for PF-06946860 PKkX X X XXiXiXiXiXiX
Blood sample for immunogenicity (ADA and NAb)kX X XXiXiXiXiXiX
Prep D1.5 banked biospecimen (serum)k,lX
PF-[ADDRESS_507908] 28 to 35 days from final dose of study drug.  May occur via Clinic or TeleHealth+home-HCP visit, per 
PI [INVESTIGATOR_400190].
c. Participants continuing to Part B only. Follow-up contact 28 to 35 days from final dose of study drug. May occur via Clinic or TeleHealth+home-HCP visit, per 
PI [INVESTIGATOR_400190]. 
d. Participant and investigator may elect to have all post-randomization study visits for Part A conducted at-home or at clinic. A  selection should be made, and efforts made, to 
have all Part A visits conducted using the same paradigm (home or clinic). If the participant chooses to do a visit at the clin ic, the Telehealth visit will not be implemented.
Additional Telehealth visits, home-HCP visits or phone calls may be scheduled, as needed per PI [INVESTIGATOR_400190]. If operationally feasi ble, a nutritional consult via telehealth with 
a central vendor will be scheduled by [CONTACT_402885] [ADDRESS_507909] udy and/or at end of study as judged 
necessary by [CONTACT_093] (eg, to assess previous findings or to assess ongoing/open AEs).
g. PRO (weekly) 7-day recall: appetite, fatigue, pain refers to the Cancer-Related Cachexia Symptom assessments for appetite and fatigue and the PROMIS pain assessment.
h. Devices (eg, weighing scales and ePRO) required for study procedures will be used at Day [ADDRESS_507910] procedures as specified, however if this becomes infeasible due to progression or compli cations of underlying disease, non- completion 
will not be considered a protocol deviation as long as the participant’s safety was preserved. Collection of safety samples shoul d be prioritized.
j. Phone Interview will be conducted by [CONTACT_402886] 10 days following the Week 4 visit (ie, Day 29-39), or at early t ermination, if feasible. For Part B, a second 
participant interview will be conducted at week 12 ±[ADDRESS_507911] at the next available time point when biospecimens are being colle cted in conjunction with a participant visit.
PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 222.INTRODUCTION
Cachexia, or anorexia -cachexia sy ndrome, is a metabolic disorder and comorbidity  that 
occurs with several chronic diseases including cancer, heart failure, chronic obstructive 
pulmonary  disease (COPD), and chronic kidney  disease (CKD).  Cachexia is multifactorial , 
and is characterized b y loss of appetite, weight, and skeletal muscle, leading to fatigue, 
functional impairment, increased treatment -related toxicity , poor qualit y of life, and reduced 
survival.  Anorexia is a key  component of the cachectic phenot ype.1A meta -analysis of 
30randomi zed controlled trials from the European Organiz ation for Research and Treatment 
of Cancer (EORTC) showed that loss of appetite correlates with poor survival in cancer 
patients with advanced disease .2
The cy tokine growth differentiation factor 15 (GDF -15), also known as Macrophage 
Inhibitory  Cytokine 1 (MIC -1), is a member of the transforming growth factor beta (TGF ) 
superfamil y.  In healthy individuals the major source of circulating GDF -15 is believed to be 
the liver, although it is also expressed by  [CONTACT_10521] s, lung and adipose tissue ;3and during 
pregnancy  it is highly  expressed by  [CONTACT_402882].4  GDF -15 is also secreted b y tumor 
cells, macrophages and damaged cells.5-8In several chronic conditions such as cancer, heart 
failure, COPD, and CKD, circulating GDF
-15 concentrations are markedl y elevated 
compared to healthy  levels.9-12  Elevated GDF -15 is associated with weight loss and 
anorexia -cachexia in patients with cancer.13
-16In addition, elevated circulating GDF -15 
levels are associated with poor outcomes and survival in many cancers, heart failure, CKD 
and COPD.17-23  In rodents and non -human primates, GDF- 15 induces anorexia and weight 
loss24-28by [CONTACT_205737] -derived -neurotrophic factor (GDNF) family  receptor 
alpha -like (GFRAL).  Furthermore, increased GDF -15 levels are associated with cachexia in 
mouse tumor models, and inhibition of GDF-15 reverses weight loss and improves survival.14  
It is h ypothesized that anorexia -cachexia in patients with can cer is largel y mediated via 
GDF -15 and that suppression of GDF -15 in these patients may  lead to improvement in 
serious aspects of their disease such as anorexia leading to unintended weight loss, fatigue 
and impaired mobility .
PF-06946860 is a recombinant humanized monoclonal antibody (immunoglobulin gamma -1 
with kappa light chains [IgG1κ]) directed against GDF- 15.  This anti -GDF -15 humanized 
monoclonal antibody  (mAb) binds to the GDF -[ADDRESS_507912] of repeated subcutaneous 
administration of PF -06946860 on appetite i n participants with advanced cancer , anorexia 
and elevated circulating GDF -15 levels. The study  will also assess secondary  and 
exploratory  endpoints including fatigue, safet yand body  weig ht. 

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 232.2.Background 
A summary  of relevant, currentl y available data is provided in this protocol. Additional 
detail, and further information for this compound, may  be found in the investigator’s 
brochure (IB).
2.2.1. Nonclinical Overview
[IP_ADDRESS]. Nonclinical Pharmacology
PF-06946860 is a potent and highl y selective binder of human GDF -15 compared to 10 other 
human transforming growth factor beta (TGF ) family members.  In vitro binding, to 
fragment cry stallizable gamma (Fc ) receptors was not observed, suggesting low potenti al to 
cause antibod y dependent cell -mediated cy totoxicity  (ADCC).  However, PF -06946860 
elicited relativel y low binding to C1q, suggesting that the potential for 
complement -dependent cy totoxicity  (CDC) cannot be ruled out.  PF -06946860 did not cause 
cytokine release in human whole blood.
Consistent with the literature24-28exogenousl y administered mouse and human GDF -15 
caused weight loss (both lean mass and fat mass) i n mice, and administration of 
PF-06946860 reversed these observations.  In a variety  of GDF -15 secreting mouse tumor 
models (HT -1080, PA0165, NSX -[ZIP_CODE] and RENCA), tumor implantation induced a 
cachectic phenot ype that was either prevented or reversed b y administration of PF -06946860.  
Treatment with PF -[ADDRESS_507913] that PF-06946860 has the potential to be a 
treatment for GDF -15 related cancer cachexia in humans.
[IP_ADDRESS]. N onclinical Pharmacokinetics and Metabolism
Details of the nonclinical PKof PF -06946860 are provided in the IB.  The PK of 
PF-06946860 in mouse was consistent with that for a typi[INVESTIGATOR_205723] G1 
(IgG1) mAb.  After weekly  subcutaneous (SC) admin istration of PF -[ADDRESS_507914] the PK of 
small molecule drugs either via cy tokine mediated effects on CYP enzy mes or transporters. 
PF-06946860 is expected to unde rgo both non- specific proteol ytic elimination and 
target -mediated elimination. As such, concomitant medications and/or disease states ,that 
alter the expression of GDF -15,may potentially  impact the elimination of PF - 06946860.
[IP_ADDRESS]. Nonclinical Safety
PF-06946860 was administered weekly  in SC studies for 13 weeks (3 months) to mice and 
for 3 -and 6 -months to cynomolgus monkey s followed by  a recovery  phase of approximately  
2 and 3 months, respectively . 

PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 24No adverse effects were observed in any of the toxicity studies conducted with PF-06946860.  
The cardiovascular and renal systems, and hematology parameters were identified as potential nonadverse targets.  Cardiovascular and renal observations were predominantly related to lower group mean organ weights but were nonadverse based on the small magnitude, lack of macroscopic, microscopic and functional correlates, and/or clinical sequelae.  Hematology findings consisted of nonadverse increases in red blood cell mass parameters.  Serum chemistry findings consisted of nonadverse increases in serum triglyceride concentration.  Other nonadverse findings related to administration of PF-06946860 included small magnitude alterations in clinical chemistry parameters, minor decreases in organ weights, zymogen granule depletion in the pancreas, minimal increases in locomotor activity in mice, and microscopic findings (mononuclear cell infiltrates of choroid plexus and glomerulus) considered secondary to antidrug antibodies (ADA) and immune complex disposition in monkeys.  Nearly all of the dosing phase findings in both species reversed by [CONTACT_52366]. 
The no-observed-adverse-effect levels (NOAELs) were the highest doses tested in the 
3-month study in mice  and the 3-month  and 6-month (20 mg/kg/week) studies in monkeys.  Systemic exposures of total PF-06946860 (maximum observed concentration [C
max], average concentration [C av] and area under the curve from the 
time of dose administration up to 168 hours [AUC 168H]) at the NOAEL in the 3-month mouse 
study were 3190 μg/mL, 2010 μg/mL and 337,000 μg•h/mL, respectively.  Systemic 
exposures of total PF-06946860 (C max,Cavand AUC 168H) at the NOAEL in monkeys were 
5520μg/mL, 4340 μg/mL and 729,000 μg•h/mL, respectively, in the 3-month study and 
934μg/mL, 786 μg/mL and 132,000 μg•h/mL, respectively, in the 6-month study.
2.2.2. Clinical Overview
PF-06946860 has been evaluated in two completed Phase 1 single dose studies (C3651001 
and C3651002) in healthy participants. A multiple dose Phase 1 study (C3651009) in cancer patients with cachexia is ongoing; no data from this ongoing study are currently available.  Clinical data from the completed studies are provided in the IB for PF-06946860. 
[IP_ADDRESS]. Safety
 
 
 
 
 CCI CCI
CCI
PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
.
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 CCI
CCI
CCI
PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 26 
 
 
 
 
 
2.3. Benefit/Risk Assessment
The C3651010 study is designed primarily to assess the effect of PF-06946860 on appetite, 
fatigue and safety in a population with advanced cancer and anorexia.
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of PF-06946860 may be found in the investigator’s brochure (IB), which is the single reference safety document (SRSD) for this study. CCI
CCI
PF-[ADDRESS_507915] been 
identified to date.Summary of Data/Rationale for Risk
Assessment of risk is based on nonclinical toxicology 
studies up to [ADDRESS_507916], including ADA/NAb monitoring will continue to be implemented. 
Study Intervention(s) PF-06946860 
Potential risks associated with PF-06946860 include the following: 
1. Injection site reactions.
2. This will be the first administration of 
PF-[ADDRESS_507917] been selected to 
ensure that only appropriate participants, who are not at apparent increased risk, are included in the study (see Section 5 ).
Adverse events and clinical laboratory results 
will be monitored on an ongoing basis.
Injection site reactions will be monitored, and 
injections sites rotated.
Use of a placebo arm. Use of a placebo arm represents a risk of lack of 
benefit for those not receiving active therapy. As there are no data on efficacy yet, this risk cannot be assessed. As the endpoint under evaluation (appetite) is 
anticipated to change rapi[INVESTIGATOR_375], the study has been designed with a short duration (6 weeks), and with the potential for participation in an 
optional OLT Part B where all participants 
would receive PF-06946860. 
The study has also been designed with, a 
2:1 randomization ratio, in order to increase participants’ chances of receiving active therapy.
PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 282.3.2. Benefit Assessment
The available clinical data , summarized in Section 2.2.2, show th at a single dos e of 
PF-06946860 as high as 300 mg SC in healthy  participants is safe and well tolerated.  
Efficacy  has not yet been studied in humans.
Based upon nonclinical data, it is hypothesized that dosing with PF -06946860 will improve 
participants appetite and support maintenance of body  weight .More detailed information 
about the known and expected benefits and risks and reasonabl y expected adverse events of 
PF-06946860 may  be found in the investigator’s brochure (IB), which is the single reference 
safet y document (SRSD) for this study.
There are cur rently  no approved therapi[INVESTIGATOR_402875].  I t is estimated that 50-80%29of 
patients with advanced malignant cancer suffer with cachexia which result s in worse 
outcomes.  Therefore, the development of PF -06946860 for the treatment of cachexia may  
satisfy  an area of high unmet need.
2.3.3. Overall Benefit /Risk Conclusion
Considering all available clinical and nonclinical data, the benefit -risk profile of 
PF-06946860 is favorable and supports continued clinical development. 
3.OBJECTIVES , ESTIMANDS AND ENDPOINTS
Part A
Objectives Endpoints Estimands
Primary
 To evaluate the early effect of 
PF-06946860 compared to 
placebo on appetite in 
participants with anorexia and 
advanced cancer. Change from baseline for patient 
reported 7 -day recall 
Cancer -Related Cachexia 
Symptom Assessment –Appetite 
score ,at Week 4. Estimand 1 (similar to 
“hypothetical”) is intended to 
provide a population level estimate 
of the tre atment effect on the 
change from baseline Appetite 
score for PF -06946860 compared 
to placebo in all evaluable 
participants under the scenario of 
no discontinuation of study 
intervention and without the 
potential confounding effects of 
prohibited medication s, regardless 
of the participants’ compliance 
with dosing ( ie,using the Censored 
analysis set) .
Secondary
 To evaluate the effect of 
PF-06946860 compared to 
placebo on appetite in 
participants with anorexia and 
advanced cancer. Change from baseline for patient 
reported 7 -day recall 
Cancer -Related Cachexia 
Symptom Assessment –Appetite 
score ,at Weeks1, 2, 3, 5 and 6. Estimand 1 , as above .

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 29Objectives Endpoints Estimands
 To evaluate the effect of 
PF-06946860 compared to 
placebo on fatigue in 
participants with anorexia and 
advanced cancer. Change from baseline for patient 
reported 7 -day recall 
Cancer -Related Cachexia 
Symptom Assessment -Fatigue 
score ,at Weeks 1, 2, 3, 4, 5and 6. Estimand 2(similar to 
“hypothetical”) is intended to 
provi de a population level estimate 
of the treatment effect on the change 
from baseline Fatigue score for 
PF-06946860 compared to placebo 
in all evaluable participants under 
the scenario of no discontinuation of 
study intervention and without the 
potential conf ounding effects of 
prohibited medications, regardless of 
the participants’ compliance with 
dosing ( ie,using the Censored 
analysis set) .
 To characterize the safety and 
tolerability of repeated 
subcutaneous administrations 
of PF -06946860 compared to 
placebo in participants with 
anorexia and advanced cancer. Incidence of adverse events and 
laboratory abnormalities, in Part A
of the study .There are no defined estimands for 
these endpoints and they will be 
analyzed using [COMPANY_007] data standards ,
as applicable.
Tertiary/Exploratory: 
 To evaluate the effect of 
PF-06 946860 compared to 
placebo on body w eight in 
participants with anorexia and 
advanced cancer. Change from baseline in body 
weight ,at Weeks 3, 4 and 6 .N/A
 To explore the relationship 
between pain and appetite and 
fatigue in participants with 
anorexia and advanced cancer . Change from baseline score for 
patient reported 7 -day recall 
PROMIS -Pain 1a ,Cancer -Related 
Cachexia Symptom 
Assessment -Fatigue score and 
Cancer -Related Cachexia 
Symptom Assessment -Appetite 
score at Weeks 1 , 2, 3, 4, 5 and 6.N/A
 To assess patient global 
impression of change of 
appetite and fatigue in 
participants with anorexia and 
advanced cancer . PGI-C (appetite), at Weeks 4 
and6.
 PGI-C (fatigue), at Weeks 4 and 6 .N/A
 To characterize the unbound 
and total PKof PF -06946860 
administered in participants 
with anorexia and a dvanced 
cancer . Serum unbound and total 
concentration sof PF -06946860 , on 
Day 1 and Weeks 3, 4 and 6.N/A
 To characterize the effect of 
PF-06946860 administration 
on circulating GDF -15
concentrations in participants 
with anorexia and advanced 
cancer. Serum concentrations of total 
GDF -15; and if feasible, unbound 
GDF -15,on Day 1 and Weeks 3, 4 
and 6.N/A

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 30Objectives Endpoints Estimands
 To assess the 
immunogenicity of 
PF-06946860 administered in 
participants with anorexia and 
advanced cancer. Incidence of ADA and, if 
applicable, N Ab,in part A of the 
study .N/A
Part B 
In addition, the following objectives will be evaluated using data from Part B , as data permit:
Objectives Endpoints Estimands
Tertiary/Exploratory:
 To assess appetite in 
participants with anorexia and 
advanced cancer , during the 
open -label treatment period. Change from baseline for patient 
reported 7 -day recall 
Cancer -Related Cachexia 
Symptom Assessment –Appetite 
score ,weekly from Week 7 to 24 . N/A
 To assess fatigue in 
participants with anorexia and 
advanced cancer , during the 
open -label treatment period. Change from baseline for patient 
reported 7 -day recall Cancer -
Related Cachexia Symptom 
Assessment –Fatigue score ,weekly 
from Week 7 to 24 .N/A
 To characterize the safety and 
tolerability of repeated 
subcutaneous administrations 
of PF -06946860 in 
participants with anorexia and 
advanced cancer, during the 
open -label treatment period. Incidence of adverse events and 
laboratory abnormalities, in Part B 
of the study .There are no defined estimands for 
these endpoints and they will be 
analyzed using [COMPANY_007] data standards, 
as applicable.
 To assess body weight in 
participants with anorexia and 
advanced cancer , during the 
open -label treatment period. Change from baseline in body 
weight ,at Weeks 12, 15, 18 ,21 
and 24 .N/A
 To explore the relationship 
between pain and 
appetite/fatigue in participants 
with anorexia and advanced 
cancer , during the open -label
treatment period. Change from baseline score for 
patient reported 7-day recall 
PROMIS -Pain 1a, Cancer -Related 
Cachexia Symptom 
Assessment -Fatigue score and 
Cancer -Related Cachexia 
Symptom Assessment -Appetite 
score ,weekly from Week 7 to 24 .N/A
 To assess patient global 
impression of change of 
appetite and fatigue in 
participants with anorexia and 
advanced cancer , during the 
open -label treatment period. PGI-C (appetite), at Week 24 .
 PGI-C (fatigue), at Week 24 .N/A

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 31Objectives Endpoints Estimands
 To characterize the unbound 
and total PKof PF -06946860 
administered in participants 
with anorexia and advanced 
cancer , during the open -label
treatment period. Serum unbound and total 
concentration sof PF -06946860 ,at 
Weeks 12, 18 and 24 .N/A
 To characterize the effect of 
PF-06946860 administra tion 
on circulating GDF -15
concentrations in participants 
with anorexia and advanced 
cancer , during the open -label
treatment period . Serum concentrations of total 
GDF -15; and if feasible, unbound 
GDF -15,at Weeks 12, 18 and 24 .N/A
 To assess the 
immunogenicity of 
PF-06946860 administered in 
participants with anorexia and 
advanced cancer , during the 
open -label treatment period. Incidence of ADA and, if 
applicable, N Ab,in Part B of the 
study .N/A
4.STUDY DESIGN
4.1.Overall Design
This is a Phase 1b study  in patients with advanced cancer, anorexia and elevated circulating 
GDF -[ADDRESS_507918] of PF- 06946860 
administration on anorexia . 
The study  will be conducted in 2 parts. The initial 6-week treatment period will be a 
randomized, double -blind, placebo- controlled, parallel group study . Participants who meet 
the entry  criteria will be randomized to study  drug (PF -06946860 or placebo).  The 6-week 
double -
blind period will consist of a total of 2 SC doses, admin istered 3 weeks apart (Q3W).  
The 6 -week double -blind treatment period will be followed by [CONTACT_402883] -label treatment 
(OLT) with PF -06946860 of up to 18 weeks ; the total duration of treatment would, therefore, 
be up to 24 weeks . 
Potential participants will attend 2 clinic visits ( Screening and Randomi zation) with the 
investigator . The Screening visit will occur no more than 28 day s and no less than 5 days, 
prior to Randomization. The 5 -day minimum duration between Screening and 
Randomization visits will ensure that all necessary data (including GDF -15 level) are 
available to inform the investigator’s assessment of eligibility . 
All study  visits following Randomization may  be conducted by  a visiting Health Care 
Professional ( HCP )at the patient’s home . During selected home- HCP visits, the investigator 
will conduct periodic Telehealth consults with the participant in order to assess patient safet y
(See Appendix 11Study  Conduct ). Should the participant elect, at Randomization, to have 

PF-[ADDRESS_507919] with all participants (whether participating in the 6-w eek double -blind 
only, or the OLT period) will be scheduled to occur at least [ADDRESS_507920] may  be done via a phone call , 
telehealth , at home or in the clinic , per investigator judgement .For stud y part B, a
home -HCP+TeleHealth (or in -Clinic) visit will be conducted. Additional follow -upmay be 
conducted for safety  evaluation, at the discretion of the investigator.
4.2.Scientific Rationale for Study Design
The primary purpose of this study  is to assess the effect of repeated subcutaneous 
administrations of PF -[ADDRESS_507921] been reported in literature in patients with a 
variet y of tumor t ypes experiencing anorexia and weight loss.  Biospecimens from health y 
adults30and patients with cancer (from both external commercial biorepositories and an 
internal study ) were analy zed for GDF -[ADDRESS_507922] cancer patients. These patients were mostl y Caucasian, age d 29- 90, 
and 
had an approximate ratio of 40 %: 60% females to males (excluding breast and ovarian 
[100% female] and prostate [100% male]).  The sample set of 739 apparently  health y 
volunteers were predominantly  Caucasian, age d20-79 and equall y distributed males and 
females . Analy sis of both the cancer and h ealth y sample sets using the [COMPANY_002] Elecs ys 
assay ,30confirmed literature -
reported elevations in GDF- 15 levels in cancer patients when
compar edto healthy  subjects (elevations ranging from 2 -fold [prostate and breast cancer] to 
5-fold [pancreati c cancer]).  An adhoc anal ysis of NSCL C patients from an internal [COMPANY_007] 
study  demonstrated that higher GDF -15 levels were associated with a reduction in body  

PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 33weight.  These data were used to determine the degree of GDF-15 elevation necessary for 
inclusion in this study. GDF-15 levels above the 95thpercentile of GDF-15 concentrations 
reported in these healthy subjects will be considered elevated . 
In order to appropriately enroll patients who may be expected to derive benefit from 
treatment with PF-06946860, severity of anorexia (See Section [IP_ADDRESS] ) will be assessed at 
Screening and prior to Randomization using a self-reported questionnaire.  Impaired appetite will be a requirement for inclusion into this study. 
Studies to evaluate the development toxicity of PF-[ADDRESS_507923] not been conducted.
Therefore, the use of a highly effective method of contraception is required (see Appendix 4 ).
4.2.2. Duration of Dosing 
The double-blind portion of this study (Part A) will be [ADDRESS_507924] on the primary endpoint, appetite, while minimizing the required duration of study participation. 
All participants completing the 6-week double-blind portion of the study will be given the 
option of receiving open-label PF-06946860 during study Part B. As efficacy has not yet been studied in a clinical setting, participation in study Part B will be optional with the purpose of providing continued access to participants who are deriving or may derive benefit(based on their own perception, along with that of their investigator).
The total duration of dosing with PF-06946860 in this study will be up to 24 weeks, as 
supported by [CONTACT_402887] ( Section 2.2.1 ).
4.2.3. Endpoints and Procedures
The key objectives of this study are to assess the effect of PF-[ADDRESS_507925] of any early termination in this fragile population. An additional assessment of appetite and fatigue endpoints across the entire 6-week double-blindperiod will be conducted. As the severity of pain may influence a participant’s level of appetite, patient reported data on pain may be used as part of exploratory analyses. Appetite, fatigue and pain will be assessed weekly via questionnaires completed by [CONTACT_102] (see Section [IP_ADDRESS] ). A small number of fit-for-purpose questions has been selected to minimize 
patient burden. Additionally, phone interviews will be conducted with the patient and a caregiver, if feasible. This will allow a qualitative assessment of the overallparticipant/caregiver experience (see Section [IP_ADDRESS] ).
Participant safety will be monitored primarily via clinical laboratory test and adverse event 
monitoring with a combination of in-clinic, home-HCP and TeleHealth visits. To supplement the standard clinical safety laboratory tests assessed at this stage of development, CRP, albumin and pre-albumin will be included as measures of nutritional status. CCI
PF-[ADDRESS_507926], will also provide data on bod y composition as part of the same body  weight 
measurement proced ure. Given the prevalence of edema in this population, the data may be
usedas part of exploratory anal yses.
As PF-06946860 is a monoclonal antibody ,immunogenicity  samples will be collected forthe 
determination of ADA and NAb, if applicable.
Sparse PF -06946860 and GDF -15 concentrations will be measured in this study  to (1) assess 
PF-06946860 exposure in this population; (2) understand the range of baseline GDF -15
values and variability  in this population; and (3) provide preliminary  information on the 
magnitude of GDF -15 response after PF -06946860 treatment. 
Banked biospecimens will be collected for exploratory pharmacogenomic/genomic/
biomarker anal ysesand retained in the Biospecimen Banking S ystem (BBS), which makes it 
possible to better understand the investigational product’s mechanism of action and to seek 
explanations for differences in, for example, exposure, tolerability , safet y, and/or efficacy not 
anticipated prior to the beginning of the stud y.
[IP_ADDRESS]. Participant Input into Design
Twelve patients and caregivers were interviewed in order to better understand what 
symptoms are most burdensome to patients and what might impact their decision to 
participate in a clinical study .  All patients had cancer (p rostate, non- small cell lung, 
colorectal or panc reatic cancers) and had experienced significant unintentional weight loss 
and other s ymptoms of cachexia.  
Patient i nput wasvaluable in informing key  outcomes. Of greatest interest were improved 
appetite and reduced fatigue, supporting the choice of appetite as the primary  endpoint for 
the study . 
Patients and caregivers also provided input on the study  design which triggered incorporation 
of options to potentially  enhance patient participation and retention, and highlighted the 
followi ng additional considerations which are anticipated to be of value to patients: 
Option for home/tele- visits with phy sician or in -person phy sician appointmen ts where 
feasible through double -blind portion of the study .
Nutritional consultations eg, via TeleHealth .This will be included, if operationally  
feasible. 
Confirmed the importance to patients of including the option to receive open -label 
treatment following double -blind period.

PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 35•Patients emphasized the significance of having their overall experiences with the 
study treatment heard by [CONTACT_1034]. This led to the incorporation of qualitative phone interviews in order to facilitate a more holistic assessment.
•Highlighted the value of appropriate training, including to home HCPs, on important 
aspects of the disease and the potential social and psychological impact. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
.CCI
CCI
CCICCI
PF-[ADDRESS_507927] completed the study if he/she has either completed Part A 
(including follow-up), or has completed Part A and has entered, and completed, the OL extension Part B.
The end of the study is defined as the date of the last visit of the last participant in the study.5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled.  The 
following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate.  All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all the following criteria apply:
Age and Sex:
1. Male or female participants ≥18 (or the minimum country-specific age of consent 
if >18) at Screening.
•Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2 ) participants.CCI
CCI
CCI
PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 37Type of Participant and Disease Characteristics:
2. Documented diagnosis of non-small cell lung, pancreatic, colorectal, prostate, breast 
or ovarian cancer which, in the treating oncologist’s assessment, is considered advanced, for example:
•Unresectable Stage III or IV non-small cell lung cancer.
•Locally advanced or metastatic pancreatic adenocarcinoma .
•Metastatic or recurrent colorectal cancer.
•Metastatic prostate cancer.
•Metastatic or recurrent breast cancer.
•Refractory ovarian cancer.
3. Meets any of the following criteria at Randomization:
i. Not currently receiving antineoplastic therapy. This may be, for example, a 
patient who: 
•Has chosen not to receive further therapy, for example for quality of life 
reasons;
•Is not indicated for future antineoplastic therapy or has exhausted all treatment 
options;
•Has stable disease where no antineoplastic therapy is judged to be necessary;
•Is taking a break between antineoplastic treatments, where the break has 
begun at least [ADDRESS_507928] 4 weeks prior to Randomization(see Section 6.5 ).
ii. Patients on standard of care systemic antineoplastic therapy or treatment without 
curative intent, (see Section 6.5 ).
4. Anorexia as defined by a score  in the Cancer-Related Cachexia Symptom 
Assessment-Appetite 7-day recall scale (see Appendix 7 ) at Screening and
Randomization.CCI
PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 385. Serum GDF-15 levels of  (as measured using the Investigational Use Only 
[COMPANY_002] Elecsys GDF 15 assay)30at Screening.
6. Participants who are assessed by [CONTACT_402888]-blind treatment period of 6 weeks . In the investigator’s judgement, the 
participant should be anticipated to be able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures during the double-blind portion of the study. 
In cases where the investigator is not the treating oncologist, the oncologist’s 
assessment of the potential participant’s suitability for inclusion must also be considered. 
Informed Consent:
7. Capable of giving signed informed consent as described in Appendix [ADDRESS_507929] the 6-week double-blind treatment period.
5.2. Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
1. Receiving tube feedings or parenteral nutrition (either total or partial) at the time of 
Screening or Randomization.
2. Current active reversible causes of decreased food intake, as determined by [CONTACT_3786].  These causes may include, but are not limited to:
•Mechanical obstructions making patient unable to eat;
•National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) Grade 3 or 4 oral mucositis.
3. Unresolved acute effects of any prior therapy, or uncontrolled symptoms (eg, pain, 
diarrhea) at Randomization that in the judgement of the PI [INVESTIGATOR_402876]. For example, uncontrolled pain may be indicated by a recent (eg, within past 15 days) change in opi[INVESTIGATOR_2512]. 
4. Current, severe gastrointestinal disease (including esophagitis, gastritis, 
malabsorption) at Randomization.CCI
PF-[ADDRESS_507930] 4 weeks
(requires magnetic resonance imaging [MRI ] confirmation) prior to S creening.  
Note that if radiation therapy  becomes necessary  for treatment of brai n metastases or 
palliative treatment after Randomization, this will not be a reason for discontinuation.
8. Participants with active, uncontrolled bacterial, fungal, or viral infection, including 
but not limited to HBV, HCV, HIV orparticipants with known AI DS-related illness. 
9. Undergoing major surgery  (central venous access placement and tumor biopsies are 
not considered major surgery ) within [ADDRESS_507931] plans to undergo major surgical procedures during 
the study .
10.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation /behavior or laboratory  abnormality  that may increase the risk 
of study  participation or, in the investigator’s judgment, make the participant 
inappropriate for the study .
Prior/Concomitant Therapy:
Part A Double- Blind treatment period only :
11.Initiation of new systemic antineoplastic therapy  (eg,chemotherap y, immunotherap y) 
within the [ADDRESS_507932] or during the 6 -week double -blind portion of the study ; stable ( ie, no 
significant change to dosage or frequency  of administration in prior 4 weeks) therap y 
is permissible. See Section 6.5 Concomitant Therapy for details. 

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 4013.Radiation therapy other than localized palliative treatment (eg,pain management for 
bone metastases) within the [ADDRESS_507933] or during the 6 -week double -blind portion of 
the study ; stable ( ie, no significant change to dosage or frequency  of administration in 
prior 4 weeks ) steroid therapy  eg, dexamethasone as part of pre -medication or daily  
oral prednisone 
is permissible . See Section 6.[ADDRESS_507934] or during the 6 -week double -blind portion of the stud y
; stable 
(ie, no significant change to dosage or frequency  of administration in prior 2 weeks) 
therap y is permissible .See Section 6.5Concomitant Therap yfor details.
Part B Open -Label treatment period: there areno restrictions on initiation of new therap y 
or changes to existing therap y during open -label treatment.
Prior/Concurrent Clinical Study Experience:
16. R eceived previous treatment with at least one dose of PF-06946860.
17.Actively  receiving a concurrent investigational agent
, or previous administration with 
an investigational drug within 30 day s (or as determined by  [CONTACT_19970]) or 
5half-lives preceding the first dose of investigational product used in this study  
(whichever is longer).
Diagnostic Assessments:
18.Positive urine drug screen for illicit drugs at Screening, with the exception of 
cann abinoids perPrior/Concomitant Therapy criteria number 12above. Resu ltsmay 
be confirmed b y a single repeat, if necessary . In addition, drugs which have been 
medically  prescribed and reported to the investigator at the Screening visit may  be 
permitted, if judged appropriate b y the investigator and permitted b y the Sponsor . 
Prescribed pain medication s (eg, opi[INVESTIGATOR_2438], morphine, hy drocodone ) do not need be 
cleared with the Sponsor.  
19.Inadequate liver function at Screening as evidenced by  [CONTACT_31617] 1of the following , which 
may be confirmed by  a single repeat, if necessary : 
Total serum bilirubin >1.5 x upper limit of normal (ULN) unless the participant 
has documented Gilbert syndrome;
Aspartate (AST) and/orAlanine aminotransferase (ALT) >3x UL N; >5.[ADDRESS_507935] 
if there is liver involvement by  [CONTACT_7879]; 

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 41Alkaline phosphatase >3x ULN . Inclusion of participants with alkaline 
phosphatase >[ADDRESS_507936] may  be acceptable if they are deemed medically  stable 
and fit for the stud y by [CONTACT_402889] s ponsor medicall y qualified 
personnel . 
20.Inadequate renal function at Screening, including crea tinine >2 mg/dL, or calculated 
Glomerular Filtration Rate (GFR) <30 mL/minute/1.73 m2as calculated b y the 
modification of diet in renal disease (MDRD ) equation.31Result may  be confirmed 
by a single repeat, if necessary .
Other Exclusions:
21.Woman who is pregnant or breast- feeding.
22. Investigat orsite staff or [COMPANY_007] employ ees directl y involved in the condu ct of the 
study , site staff otherwise supervised by  [CONTACT_093], and their respective family  
members .
5.3.Lifestyle Considerations
5.3.1. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4 )and will confirm that the participant has been instructed in its 
consistent and correct use.  At time points indicated in the SoA, the investigator or designee 
will inform the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the conversation and the participant ’s affirmation in the participant ’s 
chart ( participant s need to affirm their consistent and correct use of at least 1 of the selected 
methods of contraception).  In addition, the investigator or designee will instruct the 
participant to call immediately  if the selected contraception method is discontinued or if 
pregnancy  is known or suspected in the 
participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention . This includes partic ipants 
who consent and do not meet eligibility  criteria as well as those who are not randomized for 
administrative reasons ( eg, screening window has expi[INVESTIGATOR_5697], delay s in IP shippi[INVESTIGATOR_007], cohort 
filled). A minimal set of screen failure information is required to ensure transparent 
reporting of screen failure participants to meet the CONSORT publishing requirements and 
to respond to queries from regulatory  authorities.  Minimal information includes 
demograph y, screen failure details, eligibility  criteria, and an y SAE.

PF-[ADDRESS_507937] be 
repeated and the participant assigned a new SSID.
5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Study Intervention 
Administration 
Not Applicable.
6. STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, medical device(s), or study procedure(s) intended to be administered to a study participant according to the study protocol.
For the purposes of this protocol, study intervention refers to PF-06946860.6.1. Study Intervention(s) Administered
Intervention Name [INVESTIGATOR_16335]-06946860 Placebo
ARM Name [INVESTIGATOR_16335]-06946860 Double-Blind Treatment 
followed by [CONTACT_301985]-Label TreatmentPlacebo Double-Blind Treatment followed by 
[CONTACT_301985]-Label Treatment
Type Biologic Placebo
Dose Formulation Solution for injection Solution for injection
Unit Dose Strength(s)  Placebo
Dosage Level(s) Placebo Q3Weeks
Route of Administration Subcutaneous Subcutaneous 
Investigational Medicinal 
Product (IMP) and 
Noninvestigational 
Medicinal Product (NIMP)IMP IMP
Sourcing Provided centrally by [CONTACT_402884] 
6-mL glass vial with a 1 mL withdraw volume.  Each vial will be labeled as 
required per country requirement.Study intervention will be provided in 6-mL 
glass vial with a 1 mL withdraw volume.  Each vial will be labeled as required per 
country requirement.
Current/Former Name(s) 
or Alias(es)Not applicable Not applicableCCI
CCI
PF-[ADDRESS_507938] be administered by [CONTACT_402890] (whether administered at home or in a clinic setting).  During the double-blind portion (Part A) of the study, investigational product will be administered at a dose of 
 or placebo Q3W SC for a total of 2 doses (6 weeks). If the participant continues to 
the optional OLT period (Part B), up to 7 additional doses of PF-06946860  will be administered starting at the Week 6 visit (for participants entering the OLT period). Each dose is comprised of two [ADDRESS_507939] of care systemic antineoplastic treatment is to be administered on the same day of dosing with study drug (PF-06946860 or placebo in Part A or PF-06946860 in Part B), where feasible, the study drug will be administered prior to the standard of care antineoplastic treatment.   
6.2. Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study interventions received and any discrepancies are reported and resolved before use of the study intervention. 
2. Only participants enrolled in the study may receive study intervention and only 
authorized site staff or designated healthcare personnel may supply or administer study intervention. All study interventions must be stored in a secure, environmentally controlled, and monitored (manual or automated recording) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.  At a minimum, daily minimum and maximum temperatures for all site storage locations must be documented and available upon request.  Data for nonworking days must indicate the minimum and maximum temperatures since previously documented for all site storage locations upon return to business.
3. Any excursions from the study intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery along with any actions taken.  The site should actively pursue options for returning the study intervention to the storage conditions described in the labeling, as soon as possible.  Once an excursion is identified, the study intervention must be quarantined and not used until [COMPANY_007] provides permission to use the study intervention.  Specific details regarding the definition of an excursion and information the site should report for each excursion will be provided to the site in the IP manual.
4. Any storage conditions stated in the SRSD will be superseded by [CONTACT_78254].
5. Study interventions should be stored in their original containers.CCI
CCI
PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 446. The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records), such as the IPAL or sponsor-approved equivalent. All study interventions will be accounted for using a study intervention accountability form/record. All study intervention that is administered at home by [CONTACT_402891], both used and unused, must be returned to the investigator by [CONTACT_402891].  Returned study intervention must not be redispensed to the participants.
7. Further guidance and information for the final disposition of unused study 
interventions are provided in the IP manual. All destruction must be adequately documented.  If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by [CONTACT_4618].
Upon identification of a product complaint, notify the sponsor within [ADDRESS_507940], PF-06946860 and placebo will be prepared by 
[CONTACT_402892].  The study intervention will be administered in a blinded fashion to the participants in Part A and open-label in Part B.
6.3. Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study InterventionAllocation of participants to treatment groups will proceed through the use of an IRT system 
(IWR).  The site personnel (study coordinator or specified designee) will be required to enter or select information including, but not limited to, the user’s ID and password, the protocol number, and the participant number.  The site personnel will then be provided with a treatment assignment, randomization number, and DU or container number when study intervention is being supplied via the IRT system.  The IRT system will provide a confirmation report containing the participant number, randomization number, and DU or container number assigned.  The confirmation report must be stored in the site’s files. 
Study intervention will be administered at the study visits summarized in the SoA. 
The study-specific IRT reference manual and IP manual will provide the contact [CONTACT_22810].
In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded 
study intervention records at the site(s) to verify that randomization/dispensing has been done accurately.CCI
PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 456.3.2. Breaking the Blind 
The IRT will be programmed with blind-breaking instructions. In case of an emergency, the 
investigator has the sole responsibility for determining if unblinding of a participant’s treatment assignment is warranted. Participant safety must always be the first consideration in making such a determination. If the investigator decides that unblinding is warranted, the investigator should make every effort to contact [CONTACT_1152] a participant’s treatment assignment unless this could delay further management of the participant. If a participant’s treatment assignment is unblinded, the sponsor must be notified within [ADDRESS_507941] be recorded in the source documentation and CRF.
Part A of this study is participant- and Investigator-blinded and Sponsor-open.  Part B of the 
study will be open to the participant, Investigator, and Sponsor or Sponsor-designate personnel responsible for study monitoring activities (including all site monitoring activities).
The study-specific IRT reference manual and IP manual will provide the contact [CONTACT_22810].
6.4. Study Intervention Compliance
The study intervention will be administered to participants directly by [CONTACT_402893].  The date and time of each dose administered will be recorded in the source documents and recorded in the CRF.  The dose of study intervention and study participant identification will be confirmed at the time of dosing by [CONTACT_402894]’s home or a member of the study site staff other than the person administering the study intervention if the study intervention is administered at the clinic. 
Deviation(s) from the protocol-specified dosage regimen should be recorded in the CRF.A record of the number of the study drug (Investigational Product, PF-06946860 
 or placebo vials) administered to each participant must be maintained and 
reconciled with study intervention and compliance records.  Intervention start and stop dates, including dates for intervention delays and/or missed doses, will also be recorded in the CRF.
6.5. Concomitant Therapy
The date and time of administration of any background and/or concomitant therapi[INVESTIGATOR_402877].
Hormonal contraceptives that meet the requirements of this study are allowed to be used in 
participants who are WOCBP (see Appendix 4 ).
CCI
PF-[ADDRESS_507942] dose of IP and during Part A
Initiation of new systemic antineoplastic therapy (eg,chemotherap y, 
immunotherapy ) within the [ADDRESS_507943]
or planning to initiate antineoplastic therap y during the 6- week double -blind portion 
of the study . 
If a participant has recently  completed a course of antineoplastic therapy , the last 
dose of that therap y should be at least 4 weeks prior to Randomiz ation.
Initiation of new treatment prescribed or self -administered and known to have an 
impact on anorexia, weight loss or cachexia , including but not limited to 
mirtazapi[INVESTIGATOR_050], olanzapi[INVESTIGATOR_050], cannabinoids, within the [ADDRESS_507944] or during the 6 -week double -blind portion of the study ; stable 
(ie, no significant change to dosage or frequency  of administrati on in prior 4 weeks) 
therap y is permissible. 
Initiation of new treatment with sy stemic glucocorticoids is prohibited within the 
4weeks prior to the first dose of investigational product or during the 6 -week 
double -blind portion of the study ; stable (ie, no significant change to dosage or 
frequency  of administration in prior 4 weeks) steroid therapy  eg, dexamethasone as 
part of pre -medication or daily  oral prednisone is permissible. 
While use of glucocorticoids forantiemetic prophy laxis as part of standard of care 
treatment protocols is permitted under conditions described here, every  effort should 
be made not to administer such medications within the 7 day sprior to the Day 1 and 
Week 4 PRO assessments ( see Section 8.1.1 ).
Inhaled or topi[INVESTIGATOR_402878].
Prohibited in the [ADDRESS_507945] dose of IP and during Part A
Radiation therapy other than localized palliative care ( eg,pain management for 
bone metastases) within the [ADDRESS_507946] dose of IP, and duri ng Part A
Initiation of megestrol acetate within the [ADDRESS_507947] or during the 6 -week double -blind portion of the study ; stable 
(ie, no significant change to dosage or frequency  of administration in prior 2 weeks) 
therap y is permissible .

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 47Open -Label treatment period:
There are no restrictions on initiation of new therapy ,or changes to existing therapy ,
during the open -label treatment p artof the stud y.
6.5.1. Rescue Medic ine
There is no specific rescue therap y to reverse AEs observed with PF-[ADDRESS_507948] be provided to manage anyAEs or changes to underly ing symptoms. 
Note that , following the 6- week double blind portion of the study , there are no 
protocol -specified restrictions on concomitant medications (see Section 6.5).
6.6. Dose Modification
There is no dose modification of PF- 06946860 anticipated for a given participant in this 
study .
6.7.Intervention A fter the End of the Study
No intervention will be provided to study  participants following P art B of the study .  
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
In rare instances, it may  be necessary  for a participant to permanentl y discontinue study  
intervention (definitive discontinuation) . Reasons for definitive discontinuation of study  
intervention include the following :
Progression of 
underl yingdisease such that the investigator no longer considers 
participation appropriate, or of potential benefit to the participant .
Hospi[INVESTIGATOR_185563] .
Note that discontinuation of investigational product does not represent withdrawal from the 
study . If investigational product is permanentl y discontinued, the participant will remain in 
the study  for follow up.  See the SoA for data to be collected at the time of discontinuation of 
study  intervention and follow -up for an y further evaluations that need to be completed.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, posttreatment study  follow -up, 
and/or future collection of additional information.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 487.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request.  Reasons for 
discontinuation from the study  include the following:
Refused further follow -up;
Lost to follow -up;
Death ;
Study  terminated by  [CONTACT_3211] .
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted
.See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
If a participant withdraws from the study , he/she may  request destruction of any  remain ing 
samples taken and not tested, andthe investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected.  The sponsor may  retain and continue to use an y data 
collected before such withdrawal of consent.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was preserved.
7.2.1. Withdrawa l of C onsent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures.  The onl y 
exception to this is when a participant specificall y withdr aws consent for any further contact 
[CONTACT_78258].  Participant s should notify  the investigator in writing of the decision to 
withdraw consent from future follow- up, whenever possible.  The withdrawal of consent 
should be explained in detail in the medical records by  [CONTACT_093], as to whether the 
withdrawal is only  from further receipt of study  intervention or also from study  procedures 
and/or posttreatment study  follow -up, and entered on the appropriate CRF page.  In the event 
that vital status (whether the participant is alive or dead) is being measured, publicly  
available information should be used to determine vital status only  as appropriately  directed 
in accordance with local law.

PF-[ADDRESS_507949] be taken if a participant fails t o return to the clinic for /attend a 
required stud y visit:
The site must attempt to contact [CONTACT_402895]/or 
should continue in the study .
Before a participant is deemed lost to follow-up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record .
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD befor e performing any  study -specific procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Any changes in the timing or addition of time points for any  planned stud y assessments must 
be documented and approved by  [CONTACT_185618], but will not constitute a protocol amendment.  The I RB/EC will 
be informed of any safety issues that require alteration of t he safet y monitoring scheme or 
amendment of the ICD.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud
y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 50Procedures conducted as part of the participant’s routine clinical management ( eg, blood 
count) and obtained before signing of the ICD may be utilized for screening or baseline 
purposes provided the procedur es met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However, it is anticip ated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant .  When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possibl e.  The study  team must be informed of these incidents in a timely  manner. For 
selected procedures which are not feasible due to progression or complications of underl ying 
disease, as indicated in the SoA , non- completion will not be considered a protocol deviation 
as long as the participant’s safet y was preserved. In all cases, collection of safet y data should 
be prioritized.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instruction
s and contact [CONTACT_19987] .
The total blood sampling volume for individual participant s in this study  is approximately  
220mL.  The actual collection times of blood sampling may  chan ge.  Additional blood 
samples may  be taken for safet y assessments at times specified b y [COMPANY_007], provided the total 
volume taken during the study  does not exceed 550 mL during an y period of 60 consecutive 
days.
8.1.Efficacy Assessments
8.1.1.
Patient Reported Outcomes
All patient -reported outcome (PRO) assessments are completed electronically  by [CONTACT_402896], or at the clinic, following a schedule of assessments as per the SoA.  
Every  effort should be made to have the study  particip ant complete all patient
-reported 
outcome assessments before an y other clinical assessments that take place during a stud y 
visit.  
The PRO /eCOA Training Manual will be provided separately .
[IP_ADDRESS]. Cancer -Related Cachexia Symptom Assessment –Appetite
The Cancer -Related Cachexia Sy mptom Assessment -Appetite ( Appendix 7) is a self -reported 
questionnaire that measures the severity  of anorexia .  It was developed based on qualitative 
research with patients as well as review of literat ure and other existing relevant measures.  
The measure consists of [ADDRESS_507950] 7 day s from 0-“no appetite” to 10- “very  good appetite”.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Cancer -Related Cachexia Symptom Assessment –Fatigue
TheCancer -Related Cachexia Sy mptom Assessment -Fatigue ( Appendix 8)is a self -reported 
questionnaire that measures the severity  of fatigue.  I t was developed based on qualitative
research with patients as well as review of literature and other existing relevant measures.  
The measure consist sof [ADDRESS_507951] 7 day s from 0- “no fatigue” to 10 -“worst possible fatigue ”.
[IP_ADDRESS]. P ROMIS Pain 1a
While not considered an efficacy  endpoint, the severity  of pain may  influence a participant’s 
level of appetite.  The PROMI S Pain 1a ( Appendix 9)is a self -reported measure that assesses 
the intensity  of the 
participa nt’s pain in the past 7 day s from 0-“no pain” to 10 -“worst 
imaginable pain”. These data may  be used as part of exploratory  anal yses.
[IP_ADDRESS]. Patient Global Impression of Change (PGI -C)
The PGI -C (Appendix 10)is a measure consisting of 2 questions that asks study  participants 
to rate the overall change in their sy mptoms of appetite and fatigue since they  started the 
study  on a 7 point verbal rating scales that ranges from “Much better” to “Much worse”.
[IP_ADDRESS]. Qualitative Phone Interviews
Qualitative interviews will be conducted with the participant by [CONTACT_402897] .Additionally , where a caregiver is available and willing to participate, similar 
qualitative phone interviews may b
e conducted with a caregiver , as indicated in the SoA .
Note that both the participant and their caregive rmust provide consent ( Appendix 1 )for the
caregiver to participate in the phone interviews. 
Interviews will be conducted b y trained 
moderators and are anticipated to be approximately  
30minutes in duration. Using the transcripts and interviewer field notes, dominant trends 
will be identified in each interview and compared across all the intervie ws to describe the 
participant /caregiver experience with a focus on the themes or patterns in the way  the 
treatment experience is described, and the importance of an y improvements reported. 
Following the anal ysis, a comprehensive summary  report that full ydescribes the study  
objectives, methods, participants and results of the qualitative interviews will be prepared
and will not be reported in the CSR .
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the 
SoA.  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
Injection site reactions will be assessed as part of standard safet y/AE monitoring
.  Additional 
assessments may  be conducted at investigator discretion and/or until an y symptoms resolve.  
Injection site reactions may include but are not limited to: ery thema, induration, ecch ymosis, 
pain and pruritus.  The size and severit y of injection site reactions will be assessed and 

PF-[ADDRESS_507952] report a nd/or clinic notes.
8.2.1. Physical Examinations
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation.
A full phy sical examination will be conducted at Screening an d will include, at a minimum, 
assessments of the head, ears, ey es, nose, mouth, skin, heart and lung examinations, ly mph 
nodes, and gastrointestinal, musculoskeletal, and neurological systems. Height will also be 
measured and recorded at Screening only .
Symptom -directed assessments may  be carried out by  [CONTACT_402898] y trained HCP (eg,RN at
Home- HCP visits), if necessary . 
8.2.2. Clinical Safety Laboratory Assessments
See Appendix [ADDRESS_507953] an y 
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or up to the time of the final planned follow -up visit after the last 
dose of study  intervention should be repeated until the values return to normal or baseline or 
are no longer considered clinically  significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonab le by 
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix [ADDRESS_507954] 
25mIU/mL.  Pregnancy  tests will be performed in WOCBP at the times listed in the SoA .  
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced prior the participant ’sreceiving the study  intervention .  Pregnancy  tests will also 

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 53be done whenever 1 menstrual cy cle is missed during the active treatment period (or when 
potential pregnancy  is otherwise suspect ed) and at the end of the study .  Pregnancy  tests may  
also be repeated if requested by  [CONTACT_1202]/ECs or if required by  [CONTACT_427].  If a urine test 
cannot be confirmed as negative ( eg, an ambiguous result), a serum pregnancy  test is 
required.  In such ca ses, the participant must be excluded if the serum pregnancy  result is 
positive .
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEswill be reported b y the participa nt (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative). AEs will be assessed based on 
CTCAE 5.0.
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording e vents that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to disco ntinue 
the study  intervention (see Section 7.1). 
Each participant will be questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
informat ion in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of up to the time of the final planned follow-up visit, after the last administration 
of the 
study  intervention .
Follow -up by  [CONTACT_340757] a level acceptable to the 
investigator and [COMPANY_007] concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study  and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.

PF-[ADDRESS_507955] SAE Report Form.
Investigators are not obligated to activel y seek AE sor SAE safter the participant has 
concluded study  participation .  However, if the in vestigator learns of an y SAE, including a 
death, at an y time after a participant has completed the study , and he/she considers the event 
to be reasonably  related to the study  intervention, the investigator must promptly  report the 
SAE to [COMPANY_007] using the C T SAE Report Form .
[IP_ADDRESS].
Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_507956] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Append ix3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period , 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_507957] on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for c ompleting and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs.   Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain a dequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 55Further information on follow -up procedures is given in Appendix 3 .
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities towards th e safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.   The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRB
s/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]R sor other specific safety information ( eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD (s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposu re
Exposure to the study  interventio nunder stud y during pregnancy  or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A female participant is fo und to be pregnant while receiving or after discontinuing 
study  intervention .
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception .
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental exposure during pregnancy : 
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by [CONTACT_103444], skin contact.
A male famil y member or healthcare provider who has been exposed to the study  
intervention by [CONTACT_103444], skin contact [CONTACT_402899].

PF-[ADDRESS_507958] report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below f or information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until at least 
5terminal half -lives after the last dose.
If EDP occurs in the setting of environmental exposure, the investigator must report 
informa tion to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pr egnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, th e 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the f indings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE ( ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spont aneous abortion including miscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_507959] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigat or assesses the infant death as related or possibly
 related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case- by-case basis ( eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 

PF-[ADDRESS_507960] documen t in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeedin g while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention ( ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_19991].  
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 h ours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not create d when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women ( eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure d uring breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact [CONTACT_19994] , which may  or may  not lead to the occurrence of an AE.  Such persons 
may include healthcare providers , family members, and other roles that are involved in the 
trial participant’s care.
The investigator must report occupational exposure to [COMPANY_007] Safet y within 24 hours of the 
investigator’s awareness, regardless of whether there is an associated SAE.  The inf ormation 
must be reported using the CT SAE Report Form.  
Since the information does not pertain to a 
participant enrolled in the study , the information is not recorded on a CRF; however, a copy  
of the completed CT SAE Report Form is maintained in the inves tigator site file .
8.3.6. Cardiovascular and Death Events
Not applicable .

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 588.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable .
8.3.8. Adverse Events of Special Interest
All AESI s must be reported as an AE or SAE following the procedures described in 
Sections 8.3.[ADDRESS_507961] SAE Report Form.
[IP_ADDRESS]. Lack of Efficacy
Lack of efficacy  is report able to [COMPANY_007] Safet y only if associated with an SAE.
8.3.9. Medical Device Deficiencies
Not applicable .
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to [COMPANY_007] Safety Within 
24Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .

PF-06946860
Protocol C3651010Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 59Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_507962] SAE Report 
Form only when associated with an SAE.
8.4. Treatment of Overdose
Based on preliminary population PK/PD simulation, doses greater than approximately 
 administered when exposure is expected to be at steady-state, are projected to 
result in exposure exceeding the NOAEL from the 6-month toxicology study in monkeys(Section [IP_ADDRESS] ).  The definition of overdose for this trial is based on the operational aspects 
of the protocol design.  Given the nature of this study ie, subcutaneous dose administered in the participant’s home by a trained healthcare provider, and the allowed visit window, an overdose will be defined as more than 2 doses of PF-06946860  administered in a period of 3 weeks.
Sponsor does not recommend specific treatment for an overdose.In the event of an overdose, the investigator/treating physician should:
1. Contact [CONTACT_22840] 24 hours.2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities for at 
least 5 half-lives or 28 calendar days after the overdose of PF-06946860 (whichever is longer). The duration of monitoring required will be provided by [CONTACT_456].
3. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.
4. Overdose is reportable to Safety only when associated with an SAE.
5. Obtain blood samples for PK, PD, and/or immunogenicity analyses within 5-[ADDRESS_507963] dose of study intervention if requested by [CONTACT_7195] (determined on a case-by-case basis).
Decisions regarding dose interruptions or modifications will be made by [CONTACT_78256].CCI
CCI
PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 608.5.Pharmacokinetics 
Blood samples of approximately  6mL, to provide a minimum of 2mLserum , will be 
collected for measurement of 
serum unbound and total concentrations of PF -06946860 as 
specified in the SoA.  Instructions for the collection and handling of biological samples will 
be provided in the lab oratory manual or by  [CONTACT_456].  The actua l date and time (24 -hour 
clock time) of each sample will be recorded.
The actual times may  change, but the number of samples will remain the same.  All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing.  On dosing 
days, predose PK sample will be collected prior to IP administration. Collection of samples 
within the protocol -allowed visit win
dow ( ±1, ±3 or +7 days , as defined in SoA)will not be 
captured as a protocol deviation, as long as the exa ct time of the collection is noted on the 
source document and theCRF.
Samples will be used to evaluate the PK of PF-06946860 . Samples collected for anal yses of 
PF-06946860 concentration smay also be used to evaluate safet y or efficacy aspects related 
to concerns arising during or after the study , and/or evaluation of bioanal ytical method s, or 
for other internal exploratory  purposes.
Genetic anal yses will not be performed on these serum samples unless consent for this was 
included in the informed consent.  Participant confidentiality  will be maintained.
Samples collected for measurement of serum unbound and total concentrations of 
PF-[ADDRESS_507964] be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .Any deviations from the PK sample 
handling procedure ( eg, sample collec tion and processing steps, interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor.  
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrit y has been compromi sed.
Drug concentration information that may  unblind the study  will not be reported to 
investigat orsites or blinded personnel until the study  has been unblinded.
8.6.Pharmacodynamics
8.6.1. GDF-15
Blood samples of approximately  6mL, to provide a minimum of 2 mL  serum, will be 
collected for measurement of 
serum concentrations of total GDF- 15, and if feasible, unbound 
GDF -15 at time points specified in the SoA .  Instructions for the collection and handling of 
biological samples will be provided in the laboratory  manual or by  [CONTACT_456]. The actual 
date and time (24 -hour clock time) of each sample will be recorded.

PF-[ADDRESS_507965] nominal time relative to dosing.  On dosing 
days
, predose GDF -15 sample will be collected prior to IP administration. Collection of
samples 
within the protocol -allowed visit window (± 1, ±3 or +7 day s ,as defined in SoA )will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF.
Samples collected for PD anal yses may  also be used to evaluate safet y or efficacy  aspects 
related to concerns arising during or after the study
, and/or evaluation of bioanal ytical 
methods, or for other internal exploratory  purposes.
At Screening, serum GDF -[ADDRESS_507966] be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .  Any  deviations from the PD sample 
handling procedure ( eg, sample collection and processing steps, interim storage, or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor.  
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrit y has been compromised.
GDF-[ADDRESS_507967] report weight in either pounds (lb) or kilograms (kg), 
and be accurate to the nearest 0.2 lb (or 0.1 kg); ie, the device must be able to distinguish a 
difference between 150.4 lb (68.4 kg) versus 150.2 lb (68.
3kg).  The scale must be placed on 
a stable, flat surface.
At the Randomiz ation visit, an electronic scale will be provided to the participant for their 
use (at home) for the remainder of the stud y. Where possible, the same scale should be used 
for all body  weight measurements from the Randomi zation visit onward. 
Weight measurements should be taken under the following conditions, where feasible:
After void of urine;
After removal of shoes, socks, bulky  layers of clothing and jackets so that only  light 
clothing remains; 

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 62While remaining still during the measurement.
During each weight measurement from Randomization onward, and using electronic scale 
provided to the participant, body  composition data (including total body  water, fat mass and 
fat-free mass, if possible ) will be captured via bioelectrical impedance anal ysis (BIA) , as 
feasible .  
8.7.Genetics
8.7.1. Specified Genetics
Genetics (specified anal yses) are not evaluated in this study .
8.7.2. Banked Biospecimen sfor Genetics
A 2-mL blood sample optimized for DNA isolation Prep D1.5 will be collected as local 
regulations and IRBs/ECs allow.
Banked Biospecimens may  be used for research related to the study  intervention (s)and 
anorexia/cachexia .  Genes and other a nalytes (eg,proteins, RNA, nondrug metabolites) may  
be studied using the banked samples. 
See Appendix 5 for i
nformation regarding genetic research.  Details on processes for 
collection and shipment of these samples can be found in the laboratory  manual.
8.8.Biomarkers
There are no additional biomarkers planned for this study  aside from GDF -
15(described in 
Section 8.6 ).
8.8.1. Specified Gene Expression (RNA) Research 
Specified gene expression (RNA) research is not included in this study .
8.8.2. Specified Protein Research 
Specified protein research is not included in this study .
8.8.3. Specified Metabolomic Research 
Specified metabolomic research is not included in this study .
8.9.Immunogenicity Assessments
Blood samples of approximately  6mL, to provide a minimum of 2 mL  serum , will be 
collected for determination of ADA and NAb as specified in the SoA.  Instructions for the 
collection and handling of biological samples will be provided in the laboratory  manual or by  
[CONTACT_456].  The actual date and time (24-hour clock time) of each sample will be recorded.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 63Samples collected for determination of ADA and NAb may  also be used for additional 
characterization of the immune response, to evaluate safety  or efficacy  aspects related to 
concerns arising during or a fter the study , and/or evaluation of bioanal ytical methods, or for 
other internal exploratory purposes.
Genetic anal yses will not be performed on these serum samples unless consent for this was 
included in the informed consent.  Participant confidentiality will be maintained.
Samples will be analy zed using a validated anal ytical method in compliance with applicable 
SOPs. Samples determined to be positive for ADA may be further characterized for NAb.
The immunogenicit y samples must be processed and shipped as indicated in the instructions 
provided to the investigator site to maintain sample integrity .Any deviations from the 
immunogenicit y sample handling procedure ( eg, sample collection and processing steps, 
interim storage, or shippi[INVESTIGATOR_19944]), includ ing any  actions taken, must be documented 
and reported to the sponsor. On a case -by-case basis, the sponsor may  make a determination 
as to whether sample integrit y has been compromised.
Immunogenicit y information that may  unblind the study  will not be rep orted to investigator 
sites or blinded personnel until the study  has been unblinded.
8.10. Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDER
ATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a SAP, which will be maintained b y the sponsor.  The 
SAP may  modify  what is outlined in the protocol where appropriate; however, a ny major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Estimands and Statistical Hypotheses
9.1.1. Estimands
Estimand related to the appetite primary objective : 
Estimand 1 (similar to “hy pothetical”) is intended to provide a population level estimate of 
the treatment effect on the change from baseline Appetite score for PF -06946860 compared 
to placebo in all evaluable participants under the scenario of no discontinuation of study  
intervention and without the potential confounding effects of prohibited medications, 
regardless of the participants’ compliance with dosing ( ie,using the Censored anal ysis set).
Population: Patients with advanced cancer , anorexia and elevated circ ulating GDF -15 
levels .

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 64Variable: Change from baseline for the patient reported 7 -day recall Cancer -Related 
Cachexia Sy mptom Assessment -Appetite score at Week 4.
Intercurrent Events: 
a.Discontinuation of study  intervention -Data collected after a participant has 
discontinued study  intervention will be censored and treated as missing data .
b.
Prohibited medications - Data collected after a participant has received prohibited 
medications, that would modulate the primary  endpoint , will be censored and 
treated as missing data.  The list of concomitant medications will be reviewed 
prior to database lock to determine which would be classed as “prohibited” for 
this estimand
.
c.Inadequate compliance -Data collected after a participant h asmissed a dose will 
be censored and treated as missing data .
Missing data due to censoring, study  withdrawal or other reasons, are assumed to 
be missing at random.
Population level summary : Difference in mean change from baseline for the patient 
reported 7-day recall Cancer -Related Cachexia Symptom Assessment -Appetite score
at Week 4between PF -06946860 and placebo .
This estimand will 
similarly be applied to the appetite secondary  objective ( ie,change from 
baseline at Weeks 1 , 2, 3, 5 and 6).
Alternative estimands for the 
primary objective may be used in order to examine the 
robustness of the results and will be detailed in the SAP .
Estimand related to the fatigue secondary objective : 
Estimand 2 will be similar to Estimand 1, except for the following: 
Variable: Change from baseline for the patient reported 7 -day recall Cancer -Related 
Cachexia Sy mptom Assessment -Fatigue score at Weeks 1, 2, 3, 4, 5 and 6 .
Population level summary : Difference in mean change from baseline for the patient 
reported 7
-day recall Cancer -Related Cachexia Symptom Assessment -Fatigue score 
at Week 4 between PF- 06946860 and placebo .
Estimands related to the safety and tolerability secondary objective : 
There are no defined estimands for the incidence of treatment emergent adverse events and 
laboratory  abnormalities, and these endpoints will be anal yzed using [COMPANY_007] data standards as 
applicable.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 65Estimands related to tertiary/exploratory objectives : 
Tertiary /exploratory endpoints may  be anal yzed using similar estimands or analyz ed in a 
descriptive manner without reference to an estimand.  Other supporting estimands may  be 
used for some of the primary  and secondary  endpoints as a means to examine the robustness 
of results, compare to available literature and/or be used for future study planning as needed.  
Details of these estimands and anal yses will be presented in the SAP.
9.2.Sample Size Determination
A sufficient number of participants wil l be screened to achieve approximately  40participants 
(approximately  27 participants in the PF -06946860 200 mg Q3W arm and 13 participants in 
the placebo arm) randomly  assigned to study  intervention in approximately  a 2:1 ratio.  This 
is expected to ensur e completion of Part A of the study of approximately  30 evaluable 
participants (approximately  20 PF -06946860: 10 placebo), assuming a discontinuation rate of 
25%.   There is no required sample size for Part B of the study .
Thestudy sample size has been cho
sen to provide sufficient data for an initial assessment of 
efficacy  in the population forfacilitat inginternal decision making and may  be used for future 
study  planning .  Completion of 30 participants ,with a 2:[ADDRESS_507968] eristics in that: 
The probability  of achieving statistical significance (at the 5% significance level, 
using a [ADDRESS_507969]) for a true effect of 4versus placebo for the patient reported 
7-day recall Cancer -Related Cachexia Sy mptom Assessment -Appetite score (ranging 
0-10) at 4 weeks is approximately  80%.
An observed effect of 
2.7 versus placebo for the patient reported 7 -day recall 
Cancer -Related Cachexia Sy mptom Assessment -
Appetite score at 4 weeks should 
achieve statistical significance (at the 5% significance level, using a [ADDRESS_507970]).
A conservative estimate of the between -subject standard deviation for the change from 
baseline in thepatient reported 7- day recall Cancer -Related Cachexia Sy mptom 
Assessment -Appetite scor eof 4.2has been used.  This estimate wasbased on the observed 
variability of a similar appetite scale in a double -blind controlled clinical tria l assessing the 
effect of megestrol acetate onappetite inpatients with far-advanced cancer .32
Evaluable participants are defined as in Section 9.3. 
Participants who withdraw from the stud y will not be replaced.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 669.3.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis Set Description
Enrolled /Randomly  
assigned to stud y 
intervention"Enrolled" means a participant's, or their legall y authorized
representative’s, agreement to participate in a clinical study  
following completion of the informed consent process. 
Potential participants who are screened for the purpose of 
determining eligibility  for the study , but do not participate in 
the study , are not considered enrolled, unless otherwise 
specified b y the protocol.
Evaluable All participants randomly  assign ed to study  intervention and 
who take at least 1dose of study  intervention .Participants 
will be anal yzed according to the randomized study  
intervention.
Safety All participants randomly  assigned to study  intervention and 
who take at least [ADDRESS_507971] they actually  
received.
Defined A nalysis Set Description
Censored For participants who discontinue study  intervention ,receive 
prohibited medication and/or miss a dose , all observations 
post-discontinuation ,post-medication or post -missed dose will 
be censored and treated as missing data.
PK All participants randomly  assigned to study  intervention and 
who take at least [ADDRESS_507972] 1 PD (GDF -15) concentration value is reported.
Immunogenicit y All participants randomly  assigned to study  intervention and 
who take at least [ADDRESS_507973] 
1 ADA result is reported.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 679.4. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.  
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.4.1. General C onsiderations
For objectives relating to Part A of the study , each treatment arm (PF -06946860 or placebo) 
will be reported separately through the 6 -week double -blind treatment period only (including 
follow -up for an y participants not continuing onto Part B of the stud y).
[IP_ADDRESS]. Analyses for Continuous Endpoints 
The mixed effects repeated measures (MMRM) model will include participant as a random 
term, and baseline, time ( asa factor), baseline- by-time interaction, treatment and 
treatment -by-time interaction as fixed terms in the model.  An unstructured covariance 
matrix will be fitted to the repeated tim es within subject (other covariance matrices will be 
considered if necessary ), and the Kenward- Roger approximation will be used for estimating 
degrees of freedom .  Additional terms may  be fitted in the model ( eg,cancer ty pe , 
PROMI S-Pain 1a change from bas eline score), as appropriate.
9.4.2. Primary Endpoint(s)
Change from baseline for patient reported 7 -day recall Cancer -Related Cachexia Sy mptom 
Assessment –Appetite score will be anal yzedusing Estimand 1 and an MMRM model (as per 
Section [IP_ADDRESS]). The MMRM model will be fitted to the change from baseline at all 
post-treatment timepoints up to Week 6using theCensored analysis set. Least squares 
means (and 9 0% CIs)andmean difference s ver susplacebo (and 90% CIs), at Week 4, will be 
provided.  No adjustments will be made for multiplicity .

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 689.4.3. Secondary Endpoint(s)
Endpoint Statistical Analysis Methods
Change from baseline for patient reported 
7-day recall Cancer -Related Cachexia 
Symptom Assessment -Appetite score, at 
Weeks 1, 2, 3, [ADDRESS_507974] squares means (and 90% CI s) and mean 
differences 
versus placebo (and 90% CIs), at 
each week , will be provided.  No adjustments 
will be made for multiplicity .
Change from baseline for patient reported 
7-day recall Cancer -Related Cachexia 
Symptom Assessment -
Fatigue score, at 
Weeks 1, 2, 3, 4, 5 and 6. Change from baseline for patient reported 
7-day recall Cancer -Related Cachexia 
Symptom Assessment –
Fatigue score will be 
analyzedusing Estimand 2 and an MMRM 
model (as per 
Section [IP_ADDRESS]).  The MMRM 
model will be fitted to the change from 
baseline at all post -treatment timepoints up to 
Week [ADDRESS_507975] squares means (and 90% CI s) and mean 
differences 
versus placebo (and 90% CIs), at 
each w eeks, will be provided.  No adjustments 
will be made for multiplicity .
Incidence of adverse events and 
laboratory  abnormalities, in Part A of the 
study .All safet y anal yses will be performed on the 
safet y population. The safet y data will be 
summarized in accordance with [COMPANY_007] Data 
Standards. All safet y data will be summarized 
descriptivel y through appropriate data 
tabulation, descriptive statistics, categorical 
summaries, and graphical presentations , as 
appropriate . 
9.4.4. Tertiary/Exploratory Endpoint(s)
Details on the analysesof Tertiary /Exploratory  endpoints will be described in the SAP.
9.4.5. Other Analyses
Selected data collected at Screening may  be reported. These data include demographic data, 
prior and concomitant medications, GDF -15 levels, height, weight andappetite score .In 
addition, a subset of medical history  data will be reported; this will include primary  cancer 
diagnosis and staging at time of screening, date of initial diagnosis, body  weight history  

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 69(eg, weight 6 months ago or ‘usual’ weight prior to current cancer diagnosis) ,where feasible .  
Other data collected at screening that are used for inclusion/exclusion criteria, such as 
laboratory  data, will be considered source data, and will not be required to be reported, unless 
otherwise noted.
As permitted by  [CONTACT_33653] ,and determined b y the sponsor, the PK/PD relationship between serum 
PF-[ADDRESS_507976] on primary , secondary  and/or tertiary  endpoints 
may be explored using a population PK/PD approach. The population PK /PD analy sis, if 
conducted, will be reported in a separate report. 
Pharmacogenomic or biomarker data from Banked Biospecimens may
 be collected during or 
after the trial and retained for future anal yses; the results of such analy ses are not planned to 
be included in the CSR.
9.5.Interim Analyses
As this is a sponsor -open study ,the sponsor may  conduct unblinded reviews of the data 
during the course of the study  for the purpose of safety assessment, facilitating PK/PD 
modeling, and/or supporting clinical develo pment.
A formal i nterim anal ysis may be performed to assess efficacy and/or safety .Interim 
analysis results may  be used for internal business decisions regarding future study  planning , 
conducting a sample size re -estimation , adapting the study , orstoppi[INVESTIGATOR_16589] .  If a 
formal interim anal ysis is conducted
, details of the timing, objectives, decision criteria and 
analyseswill be documented in a n internal charter or in the final SAP.
Following completion of Part A , the data will be analy zed, and a report written.  The results 
of Part A will not be used to make an y changes to the design or conduct of Part B.  
9.6.Data Monitoring Committee or Other Independent Oversight Committee
This study  will not use an internal review committee (IRC) or a data monitoring committee 
(DMC ).

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 7010. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable pr ivacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  [CONTACT_107095]/EC by  [CONTACT_107096]/EC before the st udy is 
initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significan
t safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed ( ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immed iately . 
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that th e investigator becomes aware 
of.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 7110.1.2. Financial Disclosure
Investigators and sub investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study  to the 
participant or his/her legally  authorized representative and answer all questions regarding the 
study .  The participant or his/her legally  authorized representative should b e given sufficient 
time and opportunity  to ask questions and to decide whether or not to participate in the trial.
Participants must be informed that their participation is voluntary .Participants or their 
legally  authorized representative will be require d to sign a statement of informed consent that 
meets the requirements of 21 CFR 50, local regulations, I CH guidelines, HIPAA 
requirements, where applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  participant or his or her legally  authorized 
representative is fully  informed about the nature and objectives of the study , the sharing of 
data related to the study , and possible risks associated with participation, including the risks 
associated with the processing of the participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant.
The participan t must be informed that his/her medical records may  be examined by  [CONTACT_160439], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator fu rther must ensure that each study  participant or his or her legall y 
authorized representative is fully  informed about his or her right to access and correct his or 
her personal data and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study
 and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D.
Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participant or the participant’s legall y 
authorized representative.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 72Participants who are res creened are required to sign a new IC D.
Unless prohibited by  [CONTACT_20006]/EC decision, t he ICDwill contain a separate 
section that addresses the use of samples for optional additional research. The optional 
additional research does not requi re the collection of an y further samples.  The investigator 
or authorized designee will explain to each participant the objectives of the additional
research. Participants will be told that they  are free to refuse to participate and may  
withdraw their consent at any  time and for any  reason during the storage period. A separate 
signature [CONTACT_22862] a participant's agreement to allow specimens to be 
used for additional research. Participants who decline to participate in this optional 
additional research will not provide this separate signature .
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access.  The study  site will implement appropri ate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site will be responsible 
for determining whether a personal data breach has i n fact occurred and, if so, providing 
breach notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant- specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record identification . In 
case of data transfer, the sponsor wi ll protect the confidentiality  of participants’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations.  In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 73www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) th at evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted.  These r esults are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinical trial r esults on EudraCT for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/sub missions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website.  Clinical data, under Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods.  Clinical data, under Phase 2 of this 
policy , includes the publishing of individual participant data.  Policy  0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations.  CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses.Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 7410.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide dir ect access to source data documents.  This 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that suf ficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk- based initiatives in operations and quality  
such as risk management and mitigation strategies and analytical 
risk-based monitoring), 
methods, responsibilities ,and req uirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) ,are provided in the study  
monitoring plan (SMP).
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and r ights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 75The investigator(s) will notify thesponsor or its agents immediately  of any  regulatory
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present du ring the inspection.  The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigator will promptly  
provide copi[INVESTIGATOR_19946].  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source document s are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source document s must be 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what constitutes source data can be found in the SMP.
Description of the use of computerized sy stem is documented in the Data Management Plan .
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reas on at the sole discretion of the sponsor. Study  sites will be closed upon 
study  completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The invest igator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/ CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study  participants .
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 76Inadequate recruitm ent of participants by  [CONTACT_093];
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol
,the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or present ed at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications 
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remove any previously  undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] 
intervention -related information necessary  forthe appropriate scientific presentation or 
understanding of the study  results.
For all publications relat ing to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements fo r publication of the over all study  results 
covering all i nvestigator sites.   In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data.  Inthis case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 7710.1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_78276] (SToD).
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, participant s are provided with a contact [CONTACT_20016] .  The contact [CONTACT_4662], at a minimum, protocol and study  intervention
identifiers, participant numbers, contact [CONTACT_22850], and contact 
[CONTACT_4664] a contact [CONTACT_402900] t hat the investigator site staff cannot be reached to 
provide advice on a medical question or problem originating from another healthcare 
professional not involved in the participant ’s participation in the study .  The contact [CONTACT_107101] b y inve stigator staff if they  are seeking advice on medical questions or 
problems; however, it should be used only
 in the event that the established communication 
pathway s between the investigator site and the study  team are not available.  I t is therefore 
intended to augment, but not replace, the established communication pathway s between the 
investigator site and the study  team for advice on medical questions or problems that may  
arise during the stud y.  The contact [CONTACT_8865] b y the particip antdirectl y, 
and if a participant calls that number, he or she will be directed back to the investigator site.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 7810.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol.  Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  [CONTACT_20019] ,or as derived 
from calculated values.  These additional tests would no t require additional collection of 
blood.  Unscheduled clinical laboratory  measurements may  be obtained at any  time during 
the study  to assess any  perceived safety  issues.
Table 2. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN and creatinine
Glucose
Calcium
Sodium
Potassium
Chloride
Total 
CO 2(bicarbonate)
AST, 
ALT
Total bilirubin
Alkaline phosphatase
Uric acid
CRP
Pre-albumin
Albumin
Total proteinpH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopyaPregnancy test (β -hCG)c
At screen ingonly:
FSHb
Urine drug screening
Hepatitis B surface antigen
Hepatitis C antibody
HIV
a.Only if urine dipstick is positive for blood, protein, nitrites ,or leukocyte esterase.
b.For confirmation of post meno pausal status only.
c.Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_216483]/EC.   Serum or urine -hCG for female participant s of childbearing potential.
Investigators must document their review of each laboratory  safet y report.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 7910.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments ( eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator .  An y abnormal laboratory test 
results that meet an
y of the conditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms.
Requires additional diagnostic testing or medical/surgical intervention .
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
interventi on or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 80Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009] ’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure ( eg, endoscopy , appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) pres ent 
or detected at the start of the study that do not worsen.
Worsening of signs and symptoms of the malignancy  under study  should be 
recorded as AEs in the appropriate section of the CRF.  Disease progression 
assessed b y measurement of malignant lesions o n radiographs or other methods 
should not be reported as AEs.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met ( eg, hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_147192] h ospi[INVESTIGATOR_177257], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_402879]-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 81and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting.   Complications that occur during hospi[INVESTIGATOR_1084].   If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  means a sub stantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidenta l trauma ( eg, sprained ankle) which may interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospi[INVESTIGATOR_402880].  These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
Progression of the malignancy  under stud y (including signs and s ymptoms of 
progression) should not be reported as an SAE unless the outcome is fatal within 
the active collection period.  Hospi[INVESTIGATOR_185569] s ymptoms of disease 
progression shou
ld not be reported as an SAE.  If the malignancy  has a fatal 
outcome during the study or within the active collection period, then the event 
leading to death must be recorded as an AE on the CRF, and as an SAE with 
CTCAE Grade 5 (see the Assessment of Intensit ysection).
Suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic or 
non-pathogenic, is considered serious.  The event may  be suspected from clinical 
symptoms or laboratory  findings indicating an infection in a patient exposed to a 

PF-[ADDRESS_507977].  The terms “suspected transmission” and “transmission” are 
considered s ynon ymous.  These cases are considered unexpected and handled as 
serious expedited cases by [CONTACT_20020].  Such cases are also 
considered for reporting as product de fects, if appropriate.
10.3.3. Recording/Reporting and Follow -up of AE sand/or SAE s
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording adverse events on the CRF and 
for reporting serious adverse events on the CT SAE Report Form to [COMPANY_007] Safety .  These 
requirements are delineated for 3 t ypes of events: (1) SAEs; (2) nonserious adverse events 
(AEs); and (3) exposure to the study  intervention under study  during pregnancy  or 
breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding, and 
occupational exposureAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding .
Occupational exposure is 
not recorded.All (and EDP supplemental 
form for EDP)  
Note: I nclude all SAEs 
associated with exposure 
during pregnancy  or 
breastfeeding. Include all 
AEs/SAEs associated with 
occupational exposure.
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation ( eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 83It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety . In this case, all participa nt identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or oth er clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
GRADE Clinical Description of Severity
1 MILD adverse event
2 MODERATE adverse event
3 SEVERE adverse event
4 LIFE -THREATENING consequences; urgent intervention indicated
5 DEATH RELATED TO adverse event
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 84Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk fa ctors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred, and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to th e sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for reporting 
purposes, as defined b y the sponsor .  In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this causal 
relationship in the source documents and CRF, and report such an assessment in the 
dedicated section of the CT SAE Report Form and in accordance wi th the SAE 
reporting requirements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE or SAE as fully as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .
If a participant dies during participation in the study  or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 85The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the fac simile is not working , notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 8610.4. Appendix 4: Contraceptive Guidance 
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least [ADDRESS_507978] dose of stud y intervention,
which corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use a male condom when engaging in any  activity  that allows for 
passage of ejaculate to another person .
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 
1of the following conditions applies:
Is not a WOCBP (see defini tions below in Section 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly
 effective (with a failure 
rate of <1% per year), preferably with a low user dependency , as described below ,
during the intervention period and for at least [ADDRESS_507979] dose of study  
intervention ,which corresponds to the time needed to eliminate any  reproductive 
safet y risk of the study  intervention(s).   If a highl y effective method that is user 
dependent is chosen, a second effective method of contraception, as described below, 
must alsobe used.  The investi gator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.
Is a WOCBP and using a contraceptive method that is highly effective (with a failure 
rate of <1% per year), with high user dependency, as described below during the 
intervention period and for at least [ADDRESS_507980] dose of study  intervention,
which corresponds to the 
time needed to eliminate any  reproductive safet y risk of the 
study  intervention(s) In addition, a second effective method of contraception, as 
described below, must be used.  The investigator should evaluate the effectiveness of 
the contraceptive method in relationship to the first dose of study  intervention.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 87The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear ( eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history  
interview.  The method of documentation should be recorded in the participant’s medical 
record for the stud y.
2.Postmenopausal female :
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition, a
high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years of age and not using hormonal 
contraception or HRT. 
Female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 
if they  wish to continue their H RT during the study .  Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 8810.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependen cy
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device .
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion .
5.Vasectomized partner .
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed.   If not, an additional highl y effective method of contraception 
should be used.  The s permatogenesis cy cle is approximately  90 day s.
Highly Effective Methods That Are User Dependent
1.Combined (estrogen- and progestogen -containing) hormonal contraception associa ted 
with inhibition of ovulation :
Oral;
Intravaginal;
Transdermal .
2.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral;
Injectable .
3.Sexual abstinence :
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in re lation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 8910.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease. Therefore, where local 
regulations and IRB s/ECsallow, a blood sample will be collected for DNA anal ysis.
The scope of the genetic research may  be narrow ( eg, 1 or more candidate genes )or 
broad ( eg,the entire genome ), as appropriate to the scientific question under 
investigation .
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involved in the response to PF-
06946860 or study  interventions of this class to 
understand treatments for the disease(s) unde r study  or the disease(s) themselves.
The results of genetic analy ses may  be reported in CSR or in a separate study  
summary  ormay be used for internal decision making without being included in a 
study  report.
The sponsor will store the DNA samples in a se cure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained as indicated:
Samples for banking will be stored indefinitel y or for an other period as per local 
requirements.
Participant s may  withdraw their consent for the storage and/or use of their 
Banked 
Biospecimens at any  time by  [CONTACT_7328] a request to the investigator; in this case, any  
remaining material will be destro yed.  Data already generated from the samples will 
be retained to p rotect the integrit y of existing analyses.
Banked Biospecimens will be labeled with a code.  The key  between the code and the 
participant ’s personally  identify ing information ( eg,name, address) will be held at the 
study  site and will not be provided to t he sample bank.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 9010.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerat ors,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participant s fail to adapt and therefore are 
"susceptible" to pro gressive and serious liver injury, commonl y referred to as DILI.  
Participant s who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently  to determine if they  are an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks.  The increase in TBili ty pi[INVESTIGATOR_214318]/AL T is/are still elevated above 3 ×ULN ( ie, AST/AL T and TBili values will be 
elevated within the same lab oratory sample).  In rare instances, by  [CONTACT_20024], AST/ALT values might have decreased.  This occurrence is still regarded as a 
potential DILI.  Therefore, abnormal elevations in either AST OR ALT in addition to TBili 
that meet t he criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered important medical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions.  Participant s who present 
with the following laboratory  abnormalities should be evaluated further as pote ntial DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the n ormal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-[ADDRESS_507981]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; an y case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment.  
The possibility  of hepatic 
neoplasia (primary  or secondary ) should be considered.
In addition to repeating measurements of AST and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, total bile acids, and alkaline phosphatase.  Consideration should 
also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood 
for further testing, as needed, for further contemporaneous anal yses at the time of the 
recognized initial abnormaliti
es to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen /paracetamol (either by  [CONTACT_20025] a 
coformulated product in prescription or over -the-counter medications) , recreational drug, 
suppleme nt (herbal) use and consumption, family  history , sexual history , travel history , 
history  of contact [CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or 
allergic disease, and potential occupational exposure to chemicals, should be colle cted.  
Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging ( eg, biliary  
tract) and collection of serum sample s for acetaminophen/paracetamol drug and/or protein 
adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  
Such potential DILI (Hy’s law) 
cases are to be r eported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 9210.7. Appendix 7: Cancer -Related Cachexia Symptom Assessment –Appetite

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 9310.8. Appendix 8: Cancer -Related Cachexia Symptom Assessment –Fatigue

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 9410.9. Appendix 9: P ROMIS Pain1a

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 9510.10. Appendix 10: Patient Global Impression of Change

PF-[ADDRESS_507982] data points. Telehealth includes the exchange of healthcare information and services 
via telecommunication technologies (eg, audio, video, video- conferencing software) 
remotely , allowing the participant and the investigator to communicate on aspects of clinical 
care, including m edical advice, reminders, education, and safet y monitoring. Assessments to 
be performed during a telehealth visit are outlined in the SoA , and may  include :
Review and record stud y intervention(s), including compliance and missed doses.
Review and record an y AEs and SAEs since the last contact.   Refer to Section 8.3.
Review and record an y new concomitant medications or changes in concomitant 
medications since the last contact.
Review and record contraceptive method and results of pregnancy testing. Confirm 
that the participant is adhering to the contraception method(s) required in the 
protocol. Refer to Appendix [ADDRESS_507983] 7 days after 
randomization.
10.11.3. Home Health Visits
A home health care service may beutilized to facilitate scheduled visits per the Schedule of 
Activities.  Home health visits include a healthcare provider conducting an in- person study  
visit at the participant’s location, rather than an in -person stud y visit at the site. Additional 
details will be provided separately. 

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 9710.12. Appendix 12 Alt ernative Measures During Public Emergencies
Thealternative study  measures described in this section areto be followed during public 
emergencies, including the COVID -19 pandemic. This appendix applies for theduration of 
the COVID -
19 pandemic globall y and will become effective for other public emergencies 
only upon written notification from [COMPANY_007]. 
Use of these alternative study  measures are expected to cease upon the return of business as 
usual circumstances (including the lifting of an y quarantines and travel bans/advisories). 
10.12.1. Eligibility
While SARS -CoV2 testing is not mandated for this study , local clinical practice standards for 
testing should be followed. A patient should be excluded if he/she has a positive test result 
for SARS -
CoV2 infection, is known to have as ymptomatic infection, or is suspected of 
having SARS -CoV2. Patients with active infections are excluded from study  participation as 
per protocol language regarding eligibility  exclusions due to infection . 
10.12.2. Adverse Events and Serious Adver se Events
If a participant has COVID -19 during the study , this should be reported as an adverse event 
(AE) or serious adverse event (SAE) and appropriate medical intervention provided. The 
participant should be discontinued from the stud y. Study  treatment should continue unless 
the investigator/treating phy sician is concerned about the safet y of the participant, in which 
case temporary  or permanent discontinuation may be required. It is recommended that the 
investigator discuss permanent disconti nuation of study  intervention with the study  medical 
monitor. 

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page 9810.13. Appendix 13: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Term
Abs absolute
ADA antidrug antibodies
ADCC antibody  dependent cell -mediated cytotoxicity
AE adverse event
AESI adverse events of special interest
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC 168H area under the curve from the time of dose administration up to 
168hours
AUC inf area under the concentration -time curve from time [ADDRESS_507984] 
measurable concentration
AUC  area under the concentration -time curve from 0 to time t
AV atrioventricular
BBS Biospecimen Banking System
-hCG Beta-human chorionic gonadotropin
BIA bioelectrical impedance analy sis
BUN blood urea nitrogen
CavorCavg average concentration
CDC complement -dependent cy totoxicity
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD chronic kidney  disease
CL/F apparent clearance of drug from eg, plasma
CLIA clinical laboratory  improvement amendments
Cmax maximum observed concentration
CO 2 carbon dioxide (bicarbonate)
CONSORT Consolidated Standards of Reporting Trials
COPD chronic obstructive pulmonary  disease
COVID -[ADDRESS_507985] European Clinical Trials Database
Fc fragment cry stallizable gamma
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GDF -[ADDRESS_507986]
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therap y
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use 
ID identification
IgG1 immunoglobulin G1
IgG1κ immunoglobulin gamma -[ADDRESS_507987] model repeated measure
MRI magnetic resonance imaging
msec millisecond
N/A not applicable
NAb neutralizing antibodies
NCI National Cancer Institute
NIMP noninvestigational medicinal product
NOAEL no-observed -adverse -effect level
NSCL C non-small cell lung cancer
OL open -label
OLT open -label treatment
PD pharmacod ynamic(s)
PE physical examination
PGI-C patient global impression of change
PI [INVESTIGATOR_19959](s)
PRO patient reported outcome
PROMI S Patient -Reported Outcomes Measurement Information Sy stem
PT prothrombin time
PVC premature ventricular contraction/complex
Q3W [ADDRESS_507988] identifier
SToD study  team on demand
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
t½ terminal phase half -life
TBili total bilirubin
TEAE treatment -emergent adverse event
TGF transforming growth factor beta
Tmax time to reach C max
ULN upper limit of normal
US [LOCATION_002]
WBC white blood cell
WOCBP woman /women of childbearing potential

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].REFERENCES
1. Fearon K, Strasser F, Anker SD, et al . Definition and classification of cancer cachexia: 
an international consensus. Lancet Oncol. 2011;12(5):489-95. DOI : 10.1016/S1470 -
2045(10)[ZIP_CODE]- 7. Epub 2011 Feb 4. PMID: 21296615.
2. Quinten C, Coens C, Mauer M, et al . Baseline quality  of life as a prognost ic indicator of 
survival: a meta -analysis of individual patient data from EORTC clinical trials. Lancet 
Oncol. 2009; 10(9):865- 71. DOI: 10.1016/S1470 -2045(09)[ZIP_CODE]- 1. Epub 2009 Aug 18. 
PMID: 19695956.
3. Tsai VW, Husaini Y, Manandhar R, et al. Anorexia/cachexia of chronic diseases: a role 
for the TGF- family  cytokine MI C-1/GDF15. J Cachexia Sarcopenia Muscle. 
2012;3(4):239 -43.
4. Petry  CJ, Ong KK, Burling KA, et al. GDF15 concentrations in maternal serum 
associated with vomiting in pregnancy : the Cambridge baby  [CONTACT_205763] . BioRXIV. 
2017 Jan 1 :221267.
5. Krieg, A.J., Rankin, E.B., Chan, D., et al. Regulation of the histone demethy lase 
JMJD1A by  [CONTACT_68413] -inducible factor 1 enhances hy poxic gene expression and tumor 
growth. Mol Cell Biol, 2010. 30(1): 344 -53.
6. Albertoni, M., Shaw, P.H., Nozaki, M., et al. Anoxia induces macrophage inhibitory  
cytokine -1 (MIC -1) in glioblastoma cells independently  of p53 and HIF -1. Oncogene, 
2002. 21(27): 4212-9.
7. Akiy ama, M., Okano, K., Fukada, Y., Okano, T. Macrophage inhibitory  cytokine MIC -
1 is upregulated b y short -
wavelength light in cultured normal human dermal fibroblasts. 
FEBS Lett, 2009. 583(5): 933-7.
8. Bottner, M., Suter -Crazzolara,C, Sc hober, A., Unsicker, K. Expression of a novel 
member of the TGF -beta superfamil y, growth/differentiation factor -15/macrophage-
inhibiting cy tokine -1 (GDF -15/MIC- 1) in adult rat tissues. Cell Tissue Res, 1999. 
297(1): 103-10.
9. Wang, X., Li, Y., Tian, H., et a l. Macrophage inhibitory  cytokine 1 (M IC-1/GDF15) as 
a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer, 
2014. 14: 578.
10. Welsh, J.B., Sapi[INVESTIGATOR_205734], L .M., Kern, S.G., et al., Large -scale delineation of secreted 
protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S 
A, 2003. 100(6): 3410 -5.
11. Breit, S.N., Carrero, J.J., Wang- Wei Tsai, V., et al. Macrophage inhibitory  cytokine -1 
(MIC-1/GDF15) and mortality  in end-stage renal disease. Nephrol Dial Transplant, 
2012. 27(1): 70-5.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE]. Patel, M.S., L ee, J., Baz, M., et al. Growth differentiation factor- 15 is associated with 
muscle mass in chronic obstructive pulmonary  disease and promotes muscle wasting in 
vivo. J Cachexia Sarcopenia Muscle, 2016. 7(4): 436-48.
13. Lu, Z .H., Yang, L., Yu, J.W., et al. Weight loss correlates with macrophage inhibitory  
cytokine -1 expression and might influence outcome in patients with advanced 
esophageal squamous cell carcinoma. Asian Pac J Cancer Prev, 2014. 15(15): 6047 -52.
14. Lerner, L., Ha yes, T.G., Tao, N.,et al. Plasma growth differentiation factor 15 is 
associated with weight loss and mortality  in cancer patients. J Cachexia Sarcopenia 
Muscle, 2015. 6(4): 317-24.
15. Lerner, L., Tao, J., L iu,Q., et al. MAP3K11/GDF15 axis is a critical driver of cancer 
cachexia. J Cachexia Sarcopenia Muscle, 2016. 7(4): 467-82.
16. Lerner L, Gyuris J, Nicoletti R, et al. Growth differentiation factor -15 (GDF -15): A 
potential biomarker and therapeutic target for cancer- associated weight loss. Oncol Lett. 
2016; 12(5): 4219-23.
17. Brown, D.A., Ward, R.L., Buckhautts P, et al. MIC -1 serum level and genoty pe: 
associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res, 
2003. 9(7): 2642-50.
18. Brown, D.A., Lindmark, F., Stattin, P., et al. Macrophage inhi bitory  cytokine 1: a new 
prognostic marker in prostate cancer. Clin Cancer Res, 2009. 15(21): 6658 -64.
19. Blanco -Calvo, M., Tarrio, N., Reboredo, M., et al. Circulating levels of GDF15, MMP7 
and miR
-200c as a poor prognostic signature [CONTACT_205767]. Futur e Oncol, 2014. 
10(7): 1187-202.
20. Anand, I.S., Kempf, T., Rector, T. S., et al. Serial measurement of growth-
differentiation factor -15 in heart failure: relation to disease severity  and prognosis in the 
Valsartan Heart Failure Trial. Circulation, 2010. 122(1 4): 1387-95.
21. Rohatgi, A., Patel, P., Das, S.R., et al. Association of growth differentiation factor -15 
with coronary  atherosclerosis and mortality  in a young, multiethnic population: 
observations from the Dallas Heart Study . Clin Chem, 2012. 58(1): 172 -82.
22. Nair, V., Robinson- Cohen, C., Smith, M.R., et al. Growth Differentiation Factor -15 and 
Risk of CKD Progression. J Am Soc Nephrol, 2017. 28(7): 2233 -2240.
23. Martinez, C.H., Freeman, C.M., Nelson, J.D., et al. GDF -15 plasma levels in chronic 
obstructive pulmonary  disease are associated with subclinical coronary  artery  disease. 
Respir Res, 2017. 18(1): 42.

PF-06946860
Protocol C3651010
Final Protocol Amendment 2, 08 October 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE]. Johnen, H., L in, S., Kuffner, T., et al. Tumor -induced anorexia and weight loss are 
mediated b y the TGF -superfamil y cytokine MIC -1. Nat Med, 2007. 13(11): 1333-40.
25. Mullican, S.E., L in-
Schmidt, X., Chin, CN., et al. GFRAL is the receptor for GDF15 
and the ligand promotes weight loss in mice and nonhuman primates. Nat Med, 2017. 
23(10): 1150-1157.
26. Emmerson, P.J., Wang, F., Du, Y., et al. The metabolic effects of GDF15 are mediated 
by [CONTACT_205764]. Nat Med, 2017. 23(10): 1215 -1219.
27. Yang, L., Chang, CC, Sun, Z., et al. GFRAL is the receptor for GDF15 and is required 
for the anti -obesity effects of the ligand. Nat Med, 2017. 23(10): 1158 -1166.
28. Hsu JY , Crawley  S, Chen M, et al. Non -homeostatic body  weight regulation through a 
brainstem -restricted receptor for GDF15. Nature 2017; 550(7675): [ADDRESS_507989] of cachexia in 
chronic illness in Europe, [LOCATION_003], and Japan: facts and numbers update 2016. J Cachexia 
Sarcopenia Muscle. 2016 Dec; 7(5): 507 –509. doi: 10.1002/jcsm.[ZIP_CODE]. 
30. Elecs ys®GDF -15 package insert (2017). Documentation [COMPANY_002] Diagnostics, Bâle.
31. Levey  AS, Coresh, J, Greene, T, et al.  Using 
Standardized Serum Creatinine Values in 
the Modification of Diet in Renal Disease Study  Equation for Estimating Glomerular 
Filtration Rate. Ann Intern Med. 2006;145(4) : 247-54.
32. De Conno F, Martini C, Zecca E, et al. Megestrol acetate for anorexia in patien ts with 
far-advanced cancer: a double -blind controlled clinical trial. Eur J Cancer. [ADDRESS_507990];
34(11):1705-9.
